Gene Expression Changes In Heifers Treated Multiple Times For Bovine Respiratory Disease by Johnson, Jaymelynn Kay
GENE EXPRESSION CHANGES IN HEIFERS  
TREATED MULTIPLE TIMES FOR BOVINE 




JAYMELYNN KAY JOHNSON 
 
Bachelor of Science 




Submitted to the faculty of the Graduate College of the 
Oklahoma State University in partial fulfillment of 
the requirements for the degree of 





GENE EXPRESSION CHANGES IN HEIFERS 










Dr. Clint  Krehbiel 
Thesis Adviser 
 
Dr. Udaya DeSilva 
 
Dr. Jerry Ritchey 
 
Dr. Chris Richards 
 
Dr. A. Gordon Emslie 








 I would like to thank Drs. Ritchey, DeSilva, and Richards for serving on my 
graduate committee.  Also, big thanks to Dr. Krehbiel for serving as my advisor and 
allowing me to work on a project that was exactly what I was wanting to learn about.  I 
would also like to thank Dr. Luis Burciaga-Robles for collecting the samples and being 
my office-mate in which I utilized his presence to help in my understanding.  This project 
would not have been able to be completed without the help and advice of Dan Stein, who 
showed me the procedures for the microarray and for sharing the data analysis tools that 
he had found.   
 Additionally, I thank Ben Holland and everyone who has or is working at the 
Willard Sparks Beef Research Center for care of the cattle.  Ben was instrumental in 
organizing this whole project and I thank him for that, as well as, allowing me to “piggy-
back” my project to his set of research heifers.  I also want to thank all the graduate 
students who have helped at Sparks, especially for making the work days productive, yet 
fun at the same time. 
 Finally, but certainly not the least, I thank my family for supporting me through 
all these years of college.  The good Lord also receives the most credit because it is 










I. INTRODUCTION ........................................................................................................ 1 
 
II. REVIEW OF THE LITERATURE .............................................................................. 5 
 
Bovine Respiratory Disease .................................................................................. 5  
Bovine Viral Diarrhea Virus ................................................................................. 8 
Nutrition .............................................................................................................. 12 
Muscle, Fat, Growth, and the Immune/Endocrine Interaction ........................... 13 
The Immune System ........................................................................................... 17 
Innate Cytokines ................................................................................................. 17  
Toll-like Receptor 4 ............................................................................................ 18 
Nuclear Factor Kappa B ..................................................................................... 21 
Tumor Necrosis Factor Alpha ............................................................................ 24 
Interleukin 6 ........................................................................................................ 26 
Summary ............................................................................................................. 29 
Literature Cited ................................................................................................... 31 
 
III. USE OF MICROARRAY TO DETERMINE GENES DIFFERENTIALLY 
EXPRESSED IN MUSCLE AND SUBCUTANEOUS FAT OF HEIFERS 
NEVER TREATED OR CONSIDERED CHRONICALLY MORBID AFTER 
A 63-DAY PRECONDITIONING PROGRAM........................................................ 49 
 
Abstract ............................................................................................................... 49 
Introduction ......................................................................................................... 50 
Materials and Methods ....................................................................................... 53 
Results................................................................................................................. 60 
Discussion ........................................................................................................... 62 
Literature Cited ................................................................................................... 67 
Figures 
Table 1: RT-PCR primers in validation ......................................................... 71 
Table 2: Ontological groupings for LM and SCF .......................................... 71 
Table 3: Differentially expressed genes in LM .............................................. 72 
Table 4: Differentially expressed genes in SCF ............................................. 76 
Figure 1: Comparison of directional changes ................................................ 79 




Figure 3: Haptoglobin gene expression in SCF ............................................. 80 
Figure 4: Ingenuity® Pathway Analysis of both tissue showing genes 
in the protein ubiquitin pathway, glucocorticoid receptor signaling, 
hepatic fibrosis/hepatic stellate cell activation, and PPARα .................... 81 
Figure 6: Ingenuity® Pathway Analysis from LM and SCF showing 
the central hub for hepatocyte nuclear factor 4, alpha (HNF4A) ............. 82 
Figure 7: Ingenuity® Pathway Analysis of SCF showing a central hub 
for β-estradiol and hepatocyte nuclear factor 4, alpha (HNF4A) 
activation within the SCF tissue ............................................................... 83 
 
 
IV. EFFECT OF NUMBER OF TIMES TREATED FOR CLINICAL SIGNS OF 
BOVINE RESPIRATORY DISEASE ON GENE EXPRESSION IN 
HEIFERS DURING A 63-DAY PRECONDITIONING PERIOD .......................... 84 
 
Abstract ............................................................................................................... 84 
Introduction ......................................................................................................... 85 
Methods and Materials ....................................................................................... 89 
Results................................................................................................................. 94 
Discussion ........................................................................................................... 95 
Conclusions......................................................................................................... 98 
Literature Cited ................................................................................................... 99 
Figures 
Table 1: RT-PCR primers ............................................................................ 107 
Table 2: Biological data of heifers treated for BRD .................................... 108 
Figure 1: Fold change expression of FBXW12 in SCF ............................... 109 
Figure 2: Healthy versus chronic fold change expression of FBXW12 
in SCF tissue .......................................................................................... 109 
Figure 3: Fold change expression of FBXW12 in LM tissue ...................... 110 
Figure 4: Healthy versus chronic fold change expression of FBXW12 
in LM tissue ............................................................................................ 110 
Figure 5: Fold change expression of 26S in LM tissue ................................ 111 
Figure 6: Healthy versus chronic fold change expression of 26S in LM 
tissue ....................................................................................................... 111 
Figure 7: Fold change expression of NF-κB in SCF tissue .......................... 112 
Figure 8: Healthy versus chronic fold change expression of NF-κB in 
SCF tissue ............................................................................................... 112 
Figure 9: Fold change expression of tumor necrosis factor-α (TNF-α) 
within SCF tissue ................................................................................... 113 
Figure 10: Fold change expression of tumor necrosis factor-α (TNF-α) 
in LM tissue. ........................................................................................... 113 
Figure 11: Healthy versus chronic fold change expression of tumor 
necrosis factor-α (TNF-α) in LM tissue ................................................. 113 
Figure 12: Fold change expression of haptoglobin (HP) in SCF ................. 114 
Figure 13: Healthy versus chronic fold change expression of 








 Cattle production is a large contributor to the economy of the United States.  In 
2007 the US cattle industry contributed $74 billion in retail sales.  About half of this 
value ($36.1 billion) resulted from cattle and calf production alone.  During 2008, 27.9 
million steers and heifers and 5.8 million beef bulls and dairy cows were harvested, for a 
total harvest of 26.42 billion pounds of carcass weight.  Of the total carcass weight, 5.4% 
was exported for a total of 1.1431 billion pounds and $2.175 billion profit (USDA 
website, 2008).  Even though the beef industry is large, producers are looking for ways to 
produce the most economically efficient product due to small profit margins in cattle 
production.  Therefore, it is necessary that producers obtain maximum body weight (BW) 
gain per unit feed cost.  Research has been conducted to determine methods for 
increasing growth rate at decreasing cost.  Producing cattle involves four equally 
important aspects that are required to produce the most efficient product.  The four 
parameters include environment, health, genetics, and nutrition.  Environment includes 
housing and/or pen conditions, and providing a clean supply of water.  Health involves 
disease preventation measures such as vaccination and biosecurity as well as antibiotics 
when an animal becomes sick.  Although genetics play a huge role in animal production 




health are compromised.  A proper state of nutrition must be maintained in order to allow 
maximum expression of the genetic potential of an individual animal. 
There is an intricate interrelationship between growth, nutrition, and immune 
status.  In humans, inadequate diets result in poor appetite, malabsorption, and decreased 
growth and in turn this affects the consumption and absorption of nutrients that are 
critical for optimal immune response.  The primary nutrients in immune function are 
zinc, selenium, vitamin A, pyridoxine, and vitamin E (Chandra, 1996).  Results of human 
intervention trials indicate that modest supplements of micronutrients improve immune 
responses and more significantly, reduce the incidence of respiratory infection and 
antibiotic usage (Chandra, 1992).  However, this has not been observed in many cattle 
trials.  Cattle trials in which copper and zinc were injected or fed have evaluated humoral 
immune response.  Increases in growth and production, have been observed, although 
there has not been a significant increase or change in immune response (Salyer et al., 
2004, Nunnery et al., 2007).  Carter et al. (2002), Rivera et al. (2003), and a review by 
Duff and Galyean (2007) reported some benefits to supplementing with vitamin E, 
although average daily gain (ADG), feed efficiency (F:G), and other performance 
measures were not increased.  The authors suggested that further research is needed in 
regards to vitamin E and its effects on cattle immunological functions (Rivera et al., 
2002). 
Sick animals display a variety of clinical signs that can have a negative impact on 
cattle production efficiency.  The primary cause for concern is poor appetite because 
animals that do not eat will not grow, negatively impacting ADG (Johnson, 1997; Smith, 




experiences illness are anorexia (weight loss due to not eating), reduced locomoter 
activity, fever, motivational deficits, and inactivity, to name a few, and these also 
negatively impact animal performance and growth (Kent et al., 1992; Broussard et al., 
2001; Dantzer et al., 2001).  According to Dantzer et al. (2001) these changes in behavior 
are caused by a natural reorganization of the animal’s priorities to cope with illness.   
Klasing (1998) stated that the acute phase response is a process of nutrient 
liberation through skeletal muscle catabolism and nutrient consumption for acute phase 
protein synthesis and fever.  With this increase in hepatic demand for amino acids to 
support gluconeogenesis and the acute phase response, there is a considerably greater 
need for amino acids to support the immune response (Klasing and Barnes, 1988; Laurin 
and Klasing, 1990; Koh et al., 1996; Klasing, 1998).  This shift in priority for amino acid 
metabolism could also decrease growth of an animal. 
The cattle industry is very diverse and complex with many segments used to 
produce one product.  The first segment of the cattle industry is cow-calf operations.  
After weaning, calves may either go to a backgrounding/stocker operation that grows 
light weight calves to heavier weights before sending them to the feedlot, or the heavier 
calves may go directly to the feedlot.  Because most cow-calf operations are located in 
areas that are not around feedlots, these cattle must be shipped to areas where feedstuffs 
and feedyards are prevalent.  In a survey done by the USDA’s APHIS, approximately 
75% of cow-calf operators sell their calves through auction markets (summarized by Van 
Metre et al., 2009).  Due to most of the cattle in the industry coming from small herds, 
they are commingled at weaning time to fill truckloads.  In the process of going through 




because the immune system becomes compromised.  Shipping fever is a common disease 
that cattle get during this time.  Indeed, shipping fever or bovine respiratory disease 
(BRD) is the primary disease causing the greatest economic loss to the cattle industry.  








 Respiratory infections are relatively common in agricultural animals and are a 
major economic burden because they inhibit weight gain and somatic growth (Escobar et 
al., 2002).  Virtala et al. (1996) observed that body weight (BW) gain was decreased 
during the first month of life when calves were experiencing pneumonia.  Over the length 
of the trial they observed that for each week of pneumonia total BW gain was decreased 
by 0.8 kg (Virtala et al., 1996).   
Bovine respiratory disease is the most costly beef cattle disease in the U.S.  Costs 
associated with BRD prevention, treatment, morbidity, and mortality in groups of cattle 
have been estimated from $13.90 (Snowder et al., 2006) to $15.57 (Faber et al., 1999) per 
animal.  Annual losses to the U.S. cattle industry are estimated to approach $1 billion, 
whereas preventative and treatment costs are over $3 billion annually (Griffin, 1997).  
Snowder et al. (2006) reviewed health records for 18,112 over a 15 year period and 
observed that there was approximately a 17% incidence of BRD with a year percentage 
low of 5% and a high of 44%.  Many times health technicians or “pen riders” diagnose 
BRD when it could be another form of respiratory disease.  Common clinical symptoms 
for BRD include fever, rapid breathing, repetitive coughing, nasal or eye discharge or 




are similar if not identical to most forms of respiratory disease.  Because diagnosing all 
respiratory problems as BRD is common in the industry, Snowder et al. (2007) used all 
symptoms that could have been BRD in which the majority of the classifications were for 
pneumonia and respiratory disease (86 and 11%, respectively).  Additional disease 
classifications included for BRD were bronchitis, emphysema, pleuritis, pulmonary 
adenomatosis, upper respiratory infection, and pleural fibrosis (Snowder et al., 2007).  If 
these numbers are indicative of the whole cattle population in the U.S., then there is a 
significant incidence of BRD within the feedlot industry.   
 Bacterial pathogens implicated in acute and chronic BRD include Mannheimia 
haemolytica, Pasteurella multocida, Haemophilus somnus and Mycoplasma spp.  The 
major bacterial pathogen involved in acute BRD appears to be Mannheimia haemolytica, 
a normal commensal microorganism present in the bovine upper respiratory tract 
(Hodgson et al., 2005).  There are also four viral pathogens that are associated with BRD: 
bovine herpes-virus type-1 (BHV-1), parainfluenza type-3 virus (PI3V), bovine viral-
diarrhea virus type-1 (BVDV), and bovine respiratory syncytial virus (BRSV) (Peters et 
al., 2004).  Feedlots typically vaccinate against BHV-1-IBR-PI3-BRSV-BVDV (5-way 
viral) as part of routine processing.  These vaccines can be administered by either 
intranasal or intramuscular routes (Duff et al., 2000).   
Bovine respiratory disease can be seen at many different stages throughout an 
animal’s life.  Within the feedlot there seems to be a greater prevalence of the disease in 
the early to mid phases of finishing.  When animals are exposed to the virus or bacteria 
early in the feeding period they often experience a greater loss in carcass characteristics 




late period of feeding tended to have heavier carcasses, more retail product, less fat trim, 
and heavier bone weight than cattle that were treated for BRD at the early and mid 
periods.  They also noted that there was a decrease in external and internal measures of 
fat due to BRD, which is consistent with other reported data (Gardner et al., 1999; Roeber 
et al., 2001).  There are differing results on the impact of BRD on carcass quality.  
Snowder et al. (2007) and Gardner et al. (1999) did not observe a significant decrease in 
marbling score in cattle treated for BRD, although Roeber et al. (2001) and Montgomery 
et al. (2009) observed significant decreases in marbling score. 
Cystic fibrosis (CF) is a disease in humans that is caused by a genetic defect that 
impairs the mucous lining of the lungs.  This predisposes patients to chronic bacterial 
infection in the respiratory tract that causes lung destruction and loss of pulmonary 
function.  In CF the loss of lung function accounts for most of the morbidity and over 
90% of the mortality (Elborn et al., 1991; Davis et al., 1996; Ionescu et al., 2002).  Cystic 
fibrosis studies suggest that the host inflammatory and metabolic responses to chronic 
pulmonary infection have an impact on maintenance of body composition (Pencharz et 
al., 1984; Stutts et al., 1986; Elborn et al., 1993; Bell et al., 1996; Bell et al., 2000; 
Ionescu et al., 2000; Ionescu et al., 2002).  Changes in body composition are noted to 
possibly come from a negative energy balance resulting from an inadequate energy intake 
to meet energy demands.  Studies in humans have shown that there is a 25 to 80% greater 
energy requirement for patients that had moderate to severe lung disease from CF 
(Pencharz et al., 1984; Ionescu et al., 2002).  Ionescu et al. (2002) hypothesized that 
excessive energy expenditure in patients with CF could be caused by the increased 




metabolism due to chronic pulmonary infection, as well as an acute phase inflammatory 
response with increased circulating immunoreactive tumor necrosis factor alpha (TNF-
α), interleukin-1 (IL-1), interleukin-6 (IL-6), and counter-regulatory hormones that 
regulate the catabolic response with mobilization of fat and skeletal muscle as alternative 
energy sources (Van der Poll and Sauerwein, 1993; Ionescu et al., 2002).  Ionescu et al. 
(2002) observed, in clinically stable adults with CF and chronic P. aeruginosa infection 
of the lungs, that there was an excessive breakdown of both cellular and connective tissue 
protein, and this was correlated with the degree of impaired lung function and the 
systemic inflammatory response.  The fat-free-mass and the reduced body mass were 
likely consequences of protein breakdown, and the authors concluded that these 
relationships parallel acute phase inflammatory and catabolic host responses.  As with 
many other CF studies patients in the Ionescu et al. (2002) experiment were lipolytic.  
Lipolysis may be indicative of energy-wasting due to “futile cycling” of substrates 
between fat stores and the liver.  Tumor necrosis factor-α, IL-1, and IL-6 stimulate liver 
lipogenesis and peripheral lipolysis and may have a role in the impaired use of stored 
lipids, which increases the utilization of protein as an alternative energy substrate 
(Ionescu et al., 2002).  Potentially the effects of destruction of the lungs in CF patients 
could be similar to what is seen in chronic BRD infections in cattle.  
Bovine Viral Diarrhea Virus 
Bovine viral diarrhea virus (BVDV) causes a complex of disease problems 
including respiratory disease, infertility and fetal infection.  Fetal infection can lead to 
early embryonic death, abortion, congenital defects, stunting, or the birth of persistently 




noncytopathic biotype of BVDV by about 120 days of gestation.  PI calves are continual 
shedders of the disease if they survive past infancy.  These calves cause infection to other 
calves within their contemporary group.  PI calves shed the virus through body secretions 
including nasal discharge, saliva, semen, urine, tears, milk, and feces (Rae et al., 1987; 
Brock et al., 1991; Bezek et al., 1995; Brock et al., 1998; Larson, 2007).  There are two 
primary methods of transmission for BVDV; postnatal horizontal infection and 
gestational vertical infection.  The way to test for a PI calf is to take ear notch samples for 
immunohistochemical testing.  Decreased presence of PI animals near the herd or area 
will result in decreased prevalence of the disease.  Bovine viral diarrhea virus is primarily 
a cow-calf issue; however, it does carry over into the growth phase.  Ways to prevent this 
disease, or at least minimize it, are to vaccinate with BVDV vaccines in the unstressed, 
healthy heifer.  These females can receive a modified live vaccine so that a protective 
immune response coincides with the first four months of gestation.  In cows that have 
been previously vaccinated, it is recommended to give a shot once a year before the 
breeding season (Larson, 2007).  Titers in colostrum from BVDV seropositive dams 
provide protection in young calves (Larson, 2005).  Removing the seropositive animals 
from a herd as a biosecurity practice should help decrease the number of PI calves that 
will be produced.  Testing all animals on a farm/ranch could help stop this disease, but 
most ranches do not routinely practice testing. One method to determine if BVD is 
prevalent in a herd is to review records and determine if a large proportion of abortions or 
open females exists.  In stocker and feeder operations pregnancy is not an issue, but PI 
calves are the problem because they are the primary source of BVDV transmission to 




infected animals may have an impact on penmates and cattle in adjacent pens (Larson, 
2005). 
 In the general cattle population the prevalence of PI cattle has been reported to be 
between 0.13% and 2.0% (Bolin et al., 1985; Howard et al., 1986; Wittum et al., 1990; 
Houe et al., 1995; Larson, 2007).  Studies have reported pre-weaning mortality 
proportions of PI calves to be 20 to 83%, which can result in substantial loss in herds 
(Wittum et al., 2001; Larson, 2007), and economical loss for cow-calf producers.  Other 
economic losses that can occur from BVDV are from PI calves shedding the disease to 
other healthy calves and compromising their immune system.  Many times these diseases 
open the door for other respiratory diseases to cause illness and possibly death.  
Specifically, Martin et al. (1989), Fulton et al. (2000), and Fulton et al. (2002) observed 
that BVDV viremia and seroconversion can lead to respiratory disease outbreaks in 
feedlots.  Decreasing the incidence of BRD and BVDV are two very important areas of 
research which could help beef cattle producers. 
A Canadian immunohistochemical (IHC) and histological study looked at cattle 
that had chronic, antibiotic-resistant pneumonia, and sometimes concurrent polyarthiritis 
with infection of Mycoplasma bovis (M. bovis), BVDV, and Haemophilus somnus (H. 
somnus) (Shahriar et al., 2002).  Shahriar et al. (2002) took 48 animal cases from feedlots 
during the years 1995 to 1998 that were submitted to the lab and tested for these 
pathogens.  Shahriar et al. (2002) observed that M. bovis antigen was present in 44/48 
cases and 15/16 cases in a follow-up study conducted in 1999.  Bovine viral diarrhea 




up cases four of them were types Ib and II BVDV.  H. somnus antigen was present in the 
lung, heart, or both in 15/48 and 8/16 cases, respectively. 
Pulmonary lesions were looked at and classified from the 48 cases into three 
groups; acute, subacute, or chronic (Shahriar et al., 2002).  All stages of lesions were seen 
in all 48 cases.  In acute or early lesions they observed a small amount of 
hypereosinophilic exudates within the bronchioles and terminal airways, but the epithelial 
lining was intact.  The exudate was composed of degenerate neutrophils, macrophages, 
proteinaceous material, and necrotic debris and stained for M. bovis.  In subacute lesions, 
there was focal to multifocal loss of bronchiolar epithelium.  The bronchiolar lumen was 
dilated and filled with hypereosiophilic necrotic exudates.  M. bovis was detected mainly 
in the necrotic exudates and at the periphery of the lumen.  Most of the animals affected 
had their airways surrounded by lymphocytes and plasma cells or by large multifocal 
lymphoid aggregations.  In chronic lesions, there were multifocal, well-circumscribed 
foci of coagulative or liquefactive necrosis, with eosinophilic debris.  There was also 
degenerate neutrophils, cellular debris, and pyknotic nuclei, macrophages, and plasma 
cells mixed with fibroblasts.  M. bovis antigen was present at the margins of the necrotic 
foci and extended into the mononuclear cell layer. 
Shahriar et al. (2002) showed that mycoplasmal infection, particularly M. bovis, is 
common in chronic pneumonia of feedlot cattle and the organism is often isolated from 
the lungs.  Due to the fact that >90% of the IHC results showed M. bovis, Shahriar et al. 
(2002) suggested that M. bovis should be considered as a principal pathogen in chronic 
unresponsive pneumonia of feedlot cattle.  Even though they did observe a large number 




Mycoplasma that they were not able to isolate.  This is because the cattle used in this trial 
came from the chronic pens and had been treated many times with different antibiotics.  
Shahriar et al. (2002) also noted different lesions such as necrotizing mycocarditis, 
necrotizing tracheitis, and panniculitis, which had not been previously associated with M. 
bovis. 
Bovine viral diarrhea virus was observed in 64% of the 48 animals and 56% of 
the 16 animals, indicating a synergism between BVDV and M. bovis.  Shahriar et al. 
(2002) was certain that the BVDV they observed was a primary infection and not PI 
calves.  Bovine viral diarrhea virus infection is primarily responsible for vascular lesions 
observed primarily in the heart, but also in other tissues.  There is not a consistent 
correlation between the presence of vascular lesions and antigen observed in animals that 
have BVDV.  Incidence of vascular lesions can be affected by factors such as the stage of 
viral infection or immune status of the animal, as well as mechanisms associated with 
BVDV vasculitis (Shahriar et al., 2002). 
Nutrition 
Nutritionally deprived animals lose BW as evident by the study of Lehnert et al. 
(2006).  Microarray and real-time polymerase chain reaction (RT-PCR) analyses were 
conducted on biopsy samples from cattle that had been nutritionally deprived for 114 
days.  Lehnert et al. (2006) observed that there are several crucial aspects of BW loss-
mediated muscle atrophy, all of which may contribute to the ability to cope with and 
recover from periods of nutritional deprivation.  Specifically bovine muscles 
preferentially sacrifice fast, glycolytic muscle fibers during BW loss conditions while 




was a 2 to 6-fold decrease in expression of genes from the classes of muscle structural 
proteins, muscle metabolic enzymes, and extracellular matrix when compared to animals 
on a rapid growth diet.  Lehnert et al. (2006) observed down-regulated genes in muscle 
with roles in myogenic differentiation, maintenance of mesenchymal stem cells, 
modulation of membrane function, prevention of oxidative damage, and regulation of 
muscle protein degradation.     
Weight loss and manipulation of fatty acid profiles were also observed by Lehnert 
et al. (2006) with a significant increase in stearoyl-CoA desaturase gene expression 
observed in atrophying muscle, suggesting that increased fatty acid synthesis is part of 
the response to caloric restriction.  This study also uncovered evidence for possible 
growth-factor-mediated maintenance of stem cell compartments during atrophy as well as 
possible activation of antioxidative mechanisms (Lehnert et al., 2006). 
Muscle, Fat, Growth, and the Immune/Hormone Interactions 
A new area of research in regard to animal growth and performance is the effect 
that an immunological challenge has on muscle and fat cells.  These tissues are currently 
being considered as active secretory organs involved with immune response.  
Traditionally, adipose tissue was thought to be deposited on animals for providing excess 
energy stores.  However, a more recent view of adipose tissue is that of an active 
secretory organ, sending out and responding to signals that modulate appetite, energy 
expenditure, insulin sensitivity, endocrine and reproductive systems, bone metabolism, 
inflammation and immunity (Fantuzzi, 2005).  Adipose tissue produces and releases a 
variety of proinflammatory and anti-inflammatory factors, including the adipokines, 




TNF-α, IL-6, monocyte chemoattractant protein 1, and others.  It has been shown that a 
decrease in leptin levels might predispose an individual to increased susceptibility to 
infection caused by reduced T-cell responses in malnourished individuals (Fantuzzi, 
2005).  Adipose tissue can be divided into two major types: white adipose tissue and 
brown adipose tissue.  White adipose tissue represents the vast majority of adipose tissue 
in the organism and is the site of energy storage, whereas brown adipose tissue is used for 
nonshivering thermogenesis.  White adipose tissue cells are composed of many cell types 
(Curat et al., 2004; Fantuzzi, 2005). 
Muscle cells have been shown to express receptors for both cytokines and growth 
factors (Broussard et al., 2003).  Escobar et al. (2004) observed in studies with young 
swine infected with Porcine Reproductive & Respiratory Syndrome (PRRS; ATCC VR-
2385 isolate P-129 containing 50% tissue culture infected dose) and M. haemolytica 
(strain P5722-3, broth containing 1010 color-changing units/L) that increases in 
inflammatory cytokines increase myostatin concentrations.  Myostatin has been reported 
to inhibit growth and utilization of nutrients by growing muscle.  Escobar et al. (2004) 
suggested that the magnitude of increases in inflammatory cytokines during acute 
respiratory infection may be predictive of decreases in protein accretion and growth, 
some of which is due to increases in myostatin.  Escobar et al. (2004) hypothesized that 
these mechanisms could explain decreased weight gain and linear growth of young 
animals and human children.  Cytokines have been shown to act on skeletal muscle to 
reduce the efficacy of anabolic hormones such as IGF-I and insulin, while also directly 
influencing the synthesis and degradation of skeletal muscle protein (Broussard et al., 




source of both catabolic and anti-inflammatory cytokines and the balance between these 
could possibly participate in the modulation of protein turnover and muscle wasting 
(Alvarez et al., 2002). 
Recent evidence indicates that adipocytes and myofibers are equipped with 
functional pattern recognition receptors, and are capable of responding directly to 
pathogens and other receptor ligands.  Adipocytes and myofibers, acting as functional 
pattern recognition receptors, are active participants in the innate immune response 
producing a number of immune and metabolic regulators, including pro-inflammatory 
cytokines and adiponectin which help in regulating homeostasis (Mohamed-Ali et al., 
1998; Havel, 2002; Ding et al., 2004; Gabler and Spurlock, 2007). 
The immune system does not function independently from other physiological 
systems, but is highly integrated with normal metabolism and physiology (Klasing, 
1998).  During the past 10 years, receptors for a number of protein hormones and 
cytokines from the immune system have been shown to use common intracellular 
messenger pathways.  Cytokines and hormones act in a similar fashion and in some 
instances there has been an overlap at site receptors, especially because cells of the 
immune system have a wide variety of receptors, some of which use hormones that are 
normally regulated by the diet (Klasing, 1998).  The use of common messengers at least 
partially explains some of the redundancies between hormones and cytokines (Broussard 
et al., 2003).  Proinflammatory cytokines that are released following a pathological insult 
can act on the periphery, on the gastrointestinal tract, and in the brain to reduce food 
consumption (Broussard et al., 2001).  Lipopolysaccharide (LPS) stimulates cytokine 




lung, as well as non-immune tissues such as cardiac muscle (Frantz et al., 1999; Cowan et 
al., 2001). 
The emerging idea is that cytokines from the immune system use intracellular 
substrates that are also regulated by hormone receptors, and this regulation is likely to 
control cytokine and hormone specificity and redundancy.  This concept is consistent 
with the original ideas of Blalock (1984), in which both hormones and cytokines serve 
important messenger roles in immune-endocrine communication (Broussard et al., 2003).  
The possibility has only recently been considered, however, that hormones and cytokines 
might regulate the function of each other by using common intracellular substrates. For 
example, there is now accumulating evidence that receptors for some cytokines, such as 
IL-2, IL-4, IL-9, and interferon-γ, use intracellular docking molecules that were first 
identified for the insulin receptor (White, 1998; Broussard et al., 2003).  This implies that 
a single cell can express receptors for both a hormone and a cytokine.  Simultaneous 
activation of the cytokine receptor leads to downstream events that regulate the biological 
activity of the hormone receptor, and vice versa.  Cytokines are considered to be the 
critical intermediates that regulate and coordinate activities between the immune and 
neuroendocrine systems (Broussard et al., 2003).   
In regards to an interaction with the immune system and common growth 
promotants, most types of leukocytes express receptors for IGF-I, including T cells and 
their subsets, B cells, macrophages and neutrophils (reviewed in Kelley et al., 1992; 
Johnson, 1997; Kelley et al., 1998; Burgess et al., 1999).  Growth hormone, as well as 
IGF-I, are potent signals for priming pig (Edwards et al., 1988; Fu et al., 1991), cattle (Fu 




phagocytic myeloid cells for enhanced secretion of superoxide anion (Broussard et al., 
2001). 
The Immune System 
The elimination of pathogenic microorganisms is efficiently achieved by two 
branches of the immune system: “innate immunity” and “adaptive immunity”.  Adaptive 
immunity includes two main classes of specialized B and T cells that recognize non-self 
antigens via unique receptors on their surface.  Innate immunity appears early during 
evolution and has the ability to recognize pathogenic microorganisms by germ-line 
encoded receptors with defined specificities for highly conserved structures present on 
most pathogenic microorganisms.  Innate immunity is activated immediately after 
infection and rapidly controls microorganisms until adaptive immunity takes over (Toubi 
and Shoenfeld, 2004). 
Cytokines and Receptors in Immunity and Growth 
Cytokines play an integral role in the immune response and may adopt both 
inflammatory and anti-inflammatory roles.  Cytokines can function either locally in a 
paracrine and autocrine manner or at sites distant from the site of production in a manner 
comparable to the endocrine hormones.  Based on the review article of Gabler and 
Spurlock (2007) there are thirteen genes that act in both growth and immune responses.  
These genes are TNF-α, nuclear factor kappa B (NF-κB), IL-6, toll-like receptor 4 (TLR-
4), interferon gamma (IFNγ), interleukin-15 (IL-15), adiponectin, AdipoR1, AdipoR2, 
5’AMP activated protein kinase (AMPK), peroxisome proliferator-activated receptor 
alpha (PPARα), glucose transporter 4 (GLUT 4), and insulin growth factor one (IGF-I).  




and rats. Of these, the present project focuses on TLR-4, NF-κB, TNF-α, and IL-6 gene 
expression in cattle.  
Toll-like Receptor 4 
Toll-like receptor-4 is part of a large family of receptors that recognize pathogen-
associated molecular patterns (Frost et al., 2002).  TLRs are large sensors of microbial 
infection and are responsible for the induction of both innate and adaptive immune 
responses.  The mammalian TLR family presently consists of ten members, and because 
of all the many receptors, it provides the immune system with the ability to respond to a 
wide variety of pathogens.  Toll-like receptor-4 signaling can stimulate IL-6 mRNA 
expression in mouse skeletal muscle.  Frost et al. (2003) observed that mice that have a 
mutation in the TLR-4 gene have a greatly reduced expression of IL-6.  This could 
handicap an immune response and the ability to overcome an immunological challenge.  
TLR-mediated functions can be modulated by viral infection or activation of 
macrophages via IFN-γ; however, Franchini et al. (2006) showed that co-stimulation with 
IFN-γ or pre-infection with BVDV did not seem to change the concentrations of TLR 
mRNA transcripts.  In contrast, TLR-mediated TNF and nitric oxide (NO) production are 
affected by TLR-4, TLR-2, and TLR-3.  There is speculation that TLR-2 and TLR-4 are 
designed to recognize extracellular pathogen-associated molecular patterns (PAMPs), 
whereas TLR-3 and TLR-9 are better positioned to recognize intracellular (viral) PAMPs 
(Franchini et al., 2006).  Franchini et al. (2006) concluded that both TLR-2 and TLR-4 
agonists induce NO synthesis and TNF expression of bovine macrophages and that NO 




cytopathic BVDV.  This confirms modulation of post-TLR-agonist-binding events by 
cytokines and infectious agents (Franchini et al., 2006).   
Several reports emphasize that TLR-2 and TLR-4 can recognize a number of self 
protein (HSP) families.  Self protein families such as HSP60 and HSP70 are normally 
intracellular proteins, but can also become “danger” molecules when released under 
stress or following excessive apoptosis.  They activate vascular smooth muscle cells and 
macrophages via TLR-2 and TLR-4 to secrete pro-inflammatory cytokines such as TNF-
α and IL-12, and to over-express co-stimulatory molecules on antigen presenting cells 
(Smiley et al., 2001; Bulut et al., 2002; Toubi and Shoenfeld, 2004).  Toll-like receptor-4 
along with TLR-1 and TLR-2 are expressed in immature dendritic cells.  The expression 
of TLRs is modulated by microbial components such as LPS, CpG-DNA, microbacteria, 
and by Th1 cytokines such as IL-2, IFN-γ and TNF-α (Supajatura et al., 2001; Mellman 
and Steinman, 2001; Toubi and Shoenfeld, 2004).  The TLR family is highly 
homogenous with the IL-1R family.  Both receptors generate signals via homophilic 
interactions that when activated causes MyD88 to recruit the death domain, IL-1R-
associated kinase (IRAK).  There are four mammalian IRAK family members of which 
IRAK-4 regulates TLR 2, 3, 4, and 9.  When IRAK-4 is absent, there is impairment of 
cytokine production, including TNF-α, IL-6, and IFN-γ (Toubi and Shoenfeld, 2004).  
MyD88 is an adaptor molecule that leads to the activation of NF-κB.  Nuclear factor 
kappa B is the best defined transcription factor that is activated by TLRs (Toubi and 
Shoenfeld, 2004).  Toll-like receptor-mediated activation induces the expression of co-
stimulatory molecules such as CD80/86, and the production of IL-12, thus enabling 




T cells and the generation of an antigen specific adaptive immune response.  The specific 
adaptive immune response is mediated by either Th1 or Th2, subject to the differential 
induction of variable TLRs by MyD88.  In MyD88-deficient mice the production of IFN-
γ from CD4+ T cells was impaired following their exposure to various antigens, 
suggesting that Th1 immune response is regulated by MyD88 signaling pathways 
(Kaisho et al., 2002; Toubi and Shoenfeld, 2004).  Toll-like receptor-4 and TLR-2 on 
macrophages are triggered when a cell dies to clear up apoptotic bodies, maintaining self-
tolerance and preventing tissue damage (Toubi and Shoenfeld, 2004).   
Eriksson et al. (2003) used non-transgenic mice as a model where dendritic cells 
were loaded with heart-specific self-peptide induced CD4+ T-cell-mediated myocarditis.  
Toll-like receptor stimulation triggered self-peptide-loaded dendric cells which were 
shown to be required for disease induction (Eriksson et al., 2003).  During remission 
from acute myocarditis, TLR re-stimulation resulted in a relapse of inflammatory 
infiltrates.  It was suggested that this demonstrates how tissue damage and continuous 
activation of TLRs can provoke autoimmunity during chronic infection (Erikkson et al., 
2003; Toubi and Shoenfeld, 2004).  Toll-like receptor-4 recognizes LPS, which is unique 
to gram-negative bacteria.  This recognition also requires a second polypeptide, MD-2, 
which enhances LPS responsiveness by binding to the extracellular arm of TLR-4 (Toubi 
and Shoenfeld, 2004). 
Interferon γ and TNF-α individually induce modest levels of inducible nitric oxide 
synthase (iNOS) mRNA and NO and have a small effect on MyoD mRNA expression.  
Di Marco et al. (2005) concluded that the iNOS gene could be a common target activated 




experiments have shown that these cytokines work in the above mentioned pathway (Di 
Marco et al., 2005). 
Nuclear Factor Kappa B 
Nuclear factor kappa B binds to the promoters of many genes involved in the 
immune response.  Nuclear factor kappa B can be activated by LPS and IL-1 that are part 
of a large family of TLRs, and the first step is the proteolytic degradation of its inhibitory 
protein IκB by the proteasome (Frost et al., 2002).  Nuclear factor kappa B belongs to a 
conserved family of proteins that form multiple homodimers and heterodimers with 
transcriptional activity (Ghosh et al., 1998). In most cell types, NF-κB dimers are 
retained in the cytoplasm by their interaction with specific inhibitors known as IκBs.  The 
recognition of pathogen-associated molecular patterns such as double-stranded RNA, 
single-stranded RNA, lipopolysaccharide, or CpG oligonucleotides by membrane-
associated receptors (TLRs) and cytoplasmic sensors leads to a series of events resulting 
in the ubiquitination and proteosomal degradation of the IκB subunit. NF-κB is then 
released and translocates to the nucleus, activating the transcription of genes involved in 
innate and adaptive immunity (Langland et al., 2006; de los Santos et al., 2007; Takeuchi 
and Akira, 2007).  Frost et al. (2002) noted that NF-κB plays a role in regulating the 
TNF-α promoter in C2C12 muscle cells.  They observed that LPS decreased IκB, -α, and 
-ε levels in C2C12 cells, and this was prevented by pretreatment with MG-132, which is a 
proteasomal inhibitor.  Nuclear factor-kappa B has also been shown to induce the 
expression of IL-1β, TNF-α, and IL-8 in bovine alveolar macrophages exposed to M. 
haemolytica leukotoxin and endotoxin (Hsuan et al., 1999; Caverly et al., 2003).  This 




colostrum-deprived, Holstein steer calves and induced them with M. haemolytica by 
fiberoptic bronchoscopy.  Their results showed that tracheal antimicrobial peptide (TAP) 
and IL-8 mRNA expression correlated positively with each other.  In addition there was 
an increased translocation of NF-κB to the nuclei of epithelial cells in calves with M. 
haemolytica pneumonia (Caverly et al., 2003).   
Viral activation of NF-κB is reflected by an increase in the expression of multiple 
factors involved in the innate and adaptive immune response, including the 
proinflammatory cytokine TNF-α and the chemokine RANTES (Collart et al., 1990; 
Shakhov et al., 1990; Moriuchi et al., 1997; Pahl, 1999; de los Santos et al., 2007).  NF-
κB is also activated by bacterial cell wall and viral products, mitogens, and reactive 
oxygen species (Baeuerle and Baltimore, 1996; Rothwarf and Karin, 2000).  NF-κB has 
an integral role in innate immunity, inflammation, and apoptosis; however, its in vivo 
functions in muscle are unknown.  NF-κB is a central integration site for 
proinflammatory signals and a master regulator of related target genes which include 
cytokines and chemokines, immune-presenting receptors, antigen-presenting receptors, 
stress response and acute phase proteins, and other regulators of apoptosis, growth, and 
host defense (Cai et al., 2004).  In contrast to NF-κB being involved in muscle wasting 
with several other muscle wasting cytokines, Cai et al. (2004) observed via quantitative 
RT-PCR analyses normal muscle mRNA levels of NF-κB as well as normal circulating 
concentrations of TNF-α, IL-6, IL-1β, IFN-γ, IL-2, IL-8, IL-10, leukemia inhibitory 
factor (LIF), ciliary neuronotrophic factor (CNTF) and their respective receptors in 
MIKK mice muscle cells.  MIKK mice have muscle specific expression of IKK (IκB 




normal cytokine muscle expression, Cai et al. (2004) suggested that NF-κB acts 
downstream of cachexia-inducing factors and that its activation is not sufficient to induce 
the transcription of cytokines reportedly linked to muscle wasting.  This is a contradiction 
to NF-κB’s function in inflammation and innate immunity where many cytokines activate 
NF-κB and more are released in a positive feedback response (Baeuerle and Baltimore, 
1996; Van Antwerp et al., 1996; Delhase et al., 1999; Rothwarf and Karin, 2000; Cai et 
al., 2003).   
Muscle atrophy has been considered to be primarily activated by NF-κB and 
stimulates the proteasome machinery by activating the muscle specific E3 ligase, 
MuRF1, leading to protein decay and muscle collapse.  The NF-κB pathway also uses 
other activators that play a role in muscle degeneration/cachexia such as TNF-α and IFN-
γ.  Along with this, NF-κB expresses a wide variety of genes including those encoding 
cytokines, chemokines, adhesion molecules, and inducible effector enzymes (Ghosh and 
Karin, 2002).  The iNos-NO system is used in conjunction with NF-κB in response to 
cachexia.  Nitric oxide is an oxidative stressor in skeletal muscle of cachectic animals 
(Williams et al., 1994; Buck and Chojkier, 1996).  Regulation of iNOS via the NF-κB 
pathway is important as it is used in a mechanism in the inflammatory process and is a 
potential target to combat inflammation-related disease (Di Marco et al., 2005).  The 
iNOS gene transcription is thought to use NF-κB by the pathway where de novo 
transcribed message binds to HuR, which is an RNA-binding protein, and exports the 
message to sites for translation in the cytoplasm.  This then induces iNOS protein 




react with superoxide to form peroxynitrite, which ultimately mediates both MyoD 
mRNA decay and muscle atrophy (Di Marco et al., 2005). 
Recent reports describe a role of NF-κB in cytokine-induced cachexia both in 
myotubes and in mice (Sandri et al., 2004).  Starvation is also known to trigger this 
debilitating condition of cachexia (Cai et al., 2004; Sandri et al., 2004).  However, based 
on the Di Marco et al. (2005) results cachexia and NF-κB are not related. 
Tumor Necrosis Factor Alpha 
TNF-α is known to be important in mediating inflammation and cytotoxic 
reactions.  However, more recently it has been thought to have an active role in 
metabolism.  Broussard et al. (2003) showed that when IGF-I receptors were stimulated 
by concentrations of lower than 0.1 ng/mL of TNF-α, it inhibited de novo protein 
synthesis by 50% in myoblasts.  This interaction was suggested to provide the molecular 
basis for the cross-talk that exists for ligands in the immune and endocrine systems 
(Broussard et al., 2003).  TNF-α as well as IL-1β and IL-6 are cytokines that are 
produced by macrophages in defense of an animal’s immunological challenge.  In 
addition to these cytokines’ immunoregulatory role they also act on non-immune targets 
and have behavioral, endocrinological, and metabolic effects (Escobar et al., 2002).  
TNF-α has been shown in some cases, if it is chronically high, to result in muscle wasting 
in skeletal muscle due to protein turnover (Llovera et al., 1993).  Tumor necrosis factor-
alpha activates muscle protein degradation via the ubiquitin and ATP-dependent 
proteolytic pathway (Garcia-Martinez et al., 1993).  Wasting disease in skeletal muscle 




(2001) showed that TNF-α can induce resistance of IGF-I at target tissues and can impair 
the biological activity of the receptor.   
There are two isometric receptors for TNF-α that have been associated with cell 
death; p55 kDa (Type 1) and p75 kDa (Type 2).  The TNF-α apoptosis signaling pathway 
also includes caspase-8 (FLICE)-induced activation of acid sphingomyelinase.  
Sphingomyelinase enzymatic activity results in cleavage of sphingomyelin to ceramide 
and phosphorylcholine (Schwandner et al., 1998).  Ceramide produced by 
sphingomyelinase activates several pathways including the ceramide-activated protein 
kinase, ceramide-activated protein phosphatase, and phosphokinase C and these ceramide 
signals are known to promote apoptosis in various cell types (Mathias et al., 1998; 
Broussard et al., 2001).  Frost et al. (1997) transiently exposed human myoblasts to TNF-
α buffer and the myoblasts showed inhibition of protein synthesis.  After removing the 
cytokine, TNF-α protein synthesis was still inhibited for greater than 48 hours.  These 
observations suggest that a transient increase in plasma TNF-α concentration may impair 
protein synthesis long after the cytokine has disappeared from circulation (Frost et al., 
1997; Cooney et al., 1999). 
Skeletal muscle growth and regeneration requires fusion of progenitor 
mononucleated myoblasts into multinucleated terminally differentiated myofibers.  
Myoblasts fuse with myofibers, leading to incorporation of myoblast nuclei into 
myofibers (Novakofski and McCusker, 2001; Grounds, 2002).  Insulin like growth factor-
I increases key myogenic transcription factors that are required for myoblast fusion and 
induces specific protein synthesis such as myosin heavy chains (Arnold and Winter, 




receptor level to impair the ability of IGF-I to promote the synthesis of protein.  
Broussard et al. (2003) observed that tyrosine autophosphorylation of the alpha-chains of 
the IGF-I receptor was not affected by TNF-α.  Instead, TNF-α inhibited the ability of 
IGF-I to tyrosine phosphorylate its two major docking proteins in myoblasts, insulin 
receptor substrate 1 and insulin receptor substrate 2 (Broussard et al., 2003).  This slows 
down or stops the differentiation of muscle fibers.   
TNF-α affects nearly every component of adipose tissue biology and therefore has 
a major role in regulating energy metabolism (Sethi and Hotamisligil, 1999).  
Systemically, TNF-α has been suggested to act in the brain to cause anorexia and 
subsequent BW loss (Oliff et al., 1987), and in a paracrine fashion, it has been suggested 
to limit adiposity by causing insulin resistance (Hotamisligil et al., 1993), inhibiting 
glucose transporter gene expression (Stephens and Pekala, 1991), and decreasing adipose 
tissue lipoprotein lipase activity (Beutler et al., 1985; Fried and Zechner, 1989; Mackay 
et al., 1990).  TNF-α also alters lipid metabolism by stimulating lipolysis (Hardardottir et 
al., 1992), hepatic triglyceride synthesis, and subsequent hypertriglyceridemia (Adi et al., 
1992).  Finck and Johnson (2000) suggested that TNF-α modulates energy metabolism in 
ways that direct the animal towards a negative energy balance. 
Interleukin-6 
Interleukin-6 is an important pleiotrophic cytokine with both pro- and anti-
inflammatory properties.  Interleukin-6 is predominantly synthesized in macrophages, 
lymphocytes, liver, and spleen, but recently skeletal muscle is being recognized as a 
source of this cytokine.  Interleukin-6 produced in the muscle has been said to have both 




released from the muscle during exercise can stimulate lipolysis in adipose tissue and 
glycogenolysis in the liver (Pedersen et al., 2001; Luo et al., 2003).  Acute-phase protein 
synthesis in the liver is regulated by IL-6 in which the primary contributor of IL-6 is from 
Kupffer cells; however, it is possible that IL-6 from muscle may contribute to the 
regulation of acute-phase protein production during inflammation.  It is also possible that 
locally, IL-6 has trophic effects and may participate in tissue repair after injury and 
regeneration of muscle tissue in dystrophy and after denervation (Helgren et al., 1994; 
Kurek et al., 1996a,b; Luo et al., 2003). 
In in vitro studies of C2C12 myoblasts, when LPS, IL-1β, or TNF-α were added 
IL-6 protein concentration increased by 6-to-8-fold and mRNA concentration by 5-to-10-
fold (Frost et al., 2002).  Frost et al. (2002) also observed that LPS stimulated IL-6 
mRNA expression in both myoblasts and myotubes, but in regards to protein expression 
there was a greater increase in the myoblasts than the myotubes (Frost et al., 2002, 2003).  
Human and mouse myoblasts also express IL-6 in response to peptidoglycan from the 
cell wall of Gram-positive bacteria (Frost et al., 2003).  When doing a trial in vivo in 
mice, Frost et al. (2003) observed that after injection of LPS plasma concentrations of IL-
6 were increased.  Blood was drawn from the mice at two, six, and 18 hours after 
injection to correspond with an early, middle, and late stage of the acute-phase response.  
During the early phase there was IL-6 detected at 2 ng/mL, with peak detection at six 
hours and was still significantly elevated during the late phase (18 hours).  In mRNA 
extractions IL-6 was detected in skeletal muscle two hours after LPS administration 




six IL-6 was 20-fold greater than that of control mice but at hour 18 it returned back to 
baseline (Frost et al., 2003).   
Muscle injury also increases IL-6 mRNA as detected by Kami and Senba (1998) 
who used in situ hybridization methods on mice tissues.  Kami and Senba (1998) 
observed that IL-6 mRNA was significantly increased three hours post-trauma and the 
cells that expressed IL-6 were identified as mononucleated cells located in the 
extracellular spaces between damaged cells and in the damaged cells proper.  This 
mRNA remained present in the tissue seven days post-trauma.  No mRNA was detected 
in regenerating myotubes with centrally located myonuclei (Kami and Senba, 1998). 
Luo et al. (2003) tested the hypothesis that IL-1β stimulates IL-6 production in 
cultured myotubes and tested whether mitogen-activated protein (MAP) kinase signaling 
and NF-κB activation are involved in IL-1β-induced IL-6 production.  Luo et al. (2003) 
observed that treatment of cultured C2C12 cells for 24 hours with different 
concentrations of IL-1β showed a dose-dependent stimulation of IL-6 production with the 
max immune response seen at an IL-1β concentration of 1 ng/mL.  To test whether the 
increased IL-6 concentration was associated with gene expression and mRNA levels, Luo 
et al. (2003) ran real-time PCR and saw a >25-fold increase in IL-6 mRNA expression.  
This confirms the fact that IL-6 production is controlled by IL-1β.  Cytokine induced IL-
6 synthesis is regulated by NF-κB in many cells, but in regards to skeletal muscle remains 
a mystery.  Also, other studies have shown that the MAP kinase pathway mediates 
multiple responses to cytokine stimulation (Luo et al., 2003).  To test this hypothesis, Luo 
et al. (2003) tranfected cells for NF-κB and also added inhibitors of the MAP kinase 




They observed decreased expression of IL-6 in the cells when altering these pathways, 
thus concluding that NF-κB and the MAP kinase signaling pathway regulate the 
expression of IL-6 in IL-1β-stimulated myotubes (Luo et al., 2003). 
Summary 
There seems to be a gap in the understanding of how BRD directly impacts 
muscle, subcutaneous fat, and marbling, even though it has been well documented that 
sickness impacts growth and carcass quality.  With greater incidences of clinical signs of 
BRD there are deceases in ADG, quality grade, ribeye area, and carcass weight.  
Decreased growth and carcass quality may result from inadequate intake during times of 
sickness, or it could be that gene expression and metabolism in economically important 
tissues are changing priorities.  Instead of utilizing nutrients to increase in size, muscle 
and fat tissue might be repartitioning nutrients towards areas that have a higher demand, 
such as the immune response.  This has been observed in human, mouse, and swine 
models, but not in cattle.   
Chronic infections of BRD have not been well documented in terms of how the 
animals that survive perform.  Most of the reports have been over the histological 
findings of the calves with “chronic pneumonia”.  Chronic cattle that survive still go into 
the food chain and need to be productive.  Understanding the physiological changes that 
occur that negatively impact these cattle would be beneficial. 
In human and mouse models, as well as in vitro, the acute phase cytokines have 
negative effects on the precursors to metabolism.  These cytokines have been shown to be 
highly expressed in damaged tissues, during immune response, and by stimulation in 




causing excessive damage.  For example, TNF-α can inhibit IGF-I and has been shown to 
cause muscle wasting, anorexia, and insulin resistance, each of which could slow growth 
and performance of cattle.   
Because there is some understanding of how cytokines impact tissues in vitro, one 
purpose of the research presented herein was to determine how and where they function 
in cattle with chronic infection and after receiving multiple antimicrobial treatments.  In 
addition, an understanding of changes in gene expression that potentially slow down 
adipose tissue and longissimus muscle growth is needed and was explored.  
Understanding how BRD and chronic muscle wasting impacts cattle production was the 
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Abstract: The objective was to determine the effects of bovine respiratory disease (BRD) 
on gene expression changes using microarray analysis in growing beef heifers.  Tissue 
biopsy samples from the longissimus dorsi muscle (LM) and subcutaneous fat (SCF) 
between the 12th and 13th rib from heifers never treated against BRD (HLTH; n = 5) and 
heifers classified as chronically morbid (CHR; n = 5) were collected after a 63-d 
preconditioning period. Chronically morbid was defined as animals receiving at least 
three antimicrobial treatments and loss of BW during the previous 21 d on feed.  
Hybridizations were performed using a long oligo bovine array.  Preprocessing and 




the Bioconductor and LIMMA packages through the GenePix AutoProcessor (GPAP 
3.2).  Significance level for differentially expressed genes was set at P < 0.01 with a 
twofold change or greater.  Ontology analysis of the differentially expressed genes was 
carried out using GFINDer with emphasis on biological process and molecular function.  
To further elucidate the interaction(s) of annotated genes within the context of metabolic 
or signaling pathways, Ingenuity Pathways Analysis (IPA) was used to identify the most 
relevant biological mechanisms, pathways and functions of the differentially expressed 
genes. Of the 186 differentially expressed genes in LM (143 down- and 43 up-regulated) 
and the 121 differentially expressed genes in SCF (44 down- and 77 up-regulated), 146 
and 97, respectively, had known ontology.  Differentially expressed genes were mapped 
to pathways involved in immunological functions, metabolism, catalytic activities, 
binding, proteolysis, apoptosis, translation, transcription, growth, and transport of 
nutrients. These differences in gene expression across tissues and between treatment 
groups will provide a better understanding of the impact BRD has on immune response 
and animal growth. 
 




 Respiratory infections are relatively common in domestic livestock and are a 
major economic burden because they inhibit weight gain and somatic growth (Escobar et 




during the first month of life when calves were experiencing pneumonia.  In addition, if 
calves were still experiencing pneumonia during the third month of life, for each week of 
clinical signs there was a 96 g decrease in average daily gain (ADG), and over the trial 
total BW gain was decreased by 0.8 kilograms (Virtala et al., 1996).  Bovine respiratory 
disease (BRD) is the most costly disease for beef cattle producers in the U.S.  Costs 
associated with BRD prevention, treatment, morbidity, and mortality have been estimated 
from $13.90 (Snowder et al., 2006) to $15.57 (Faber et al., 1999) per animal.  Annual 
losses to the U.S. cattle industry are estimated to approach $1 billion, whereas 
preventative and treatment costs are over $3 billion annually (Griffin, 1997).  Clinical 
symptoms for BRD include fever, rapid breathing, repetitive coughing, nasal or eye 
discharge or both, diarrhea, dehydration, and appetite depression (Snowder et al., 2007).  
In a 15-year data set with 18,112 feedlot cattle, Snowder et al. (2007) observed that there 
was approximately a 17% incidence of BRD with a year percentage low of 5% and a high 
of 44%.  If these numbers are indicative of the whole cattle population in the U.S., then 
there is a significant incidence of BRD within the feedlot industry.   
 Bovine respiratory disease can occur at many stages throughout an animal’s life.  
Within the feedlot there seems to be a greater incidence of the disease in the early to mid 
phases of finishing.  When animals are exposed to one or a combination of viruses and 
bacteria early in the feeding period they often experience a greater loss in ADG and 
carcass quality (Snowder et al., 2007).  A decrease in external and internal fat measures 
due to BRD has also been observed (Gardner et al., 1999; Roeber et al., 2001). 
Cystic fibrosis (CF) is a disease in humans that is caused by a genetic defect that 




infection in the respiratory tract that causes lung destruction and loss of pulmonary 
function.  In CF the loss of lung function accounts for most of the morbidity and over 
90% of the mortality (Elborn et al., 1991; Davis et al., 1996; Ionescu et al., 2002).  In 
regards to CF, studies suggest that the host inflammatory and metabolic responses to 
chronic pulmonary infection have an impact on maintenance of body composition as 
summarized by Ionescu et al. (2002).  Changes in body composition are noted to possibly 
result from a negative energy balance resulting from inadequate energy intake to meet 
energy demands.  Studies in humans have shown that there is a 25 to 80% greater energy 
requirement for patients that had moderate to severe lung disease from CF (Pencharz et 
al., 1984; Ionescu et al., 2002).  Ionescu et al. (2002) hypothesized that excessive energy 
expenditure in CF patients may result from the increased energy cost of breathing due to 
altered pulmonary mechanics, catabolic intermediary metabolism due to chronic 
pulmonary infection, or an acute phase inflammatory response. 
Microarrays are a useful functional genomics tool to study the expression of genes 
at specific times in cells or tissues.  Oligonucleotide microarrays are very useful 
especially in comparison to cDNA microarrays, because they can identify genes that are 
expressed in low abundance and are not represented in available cDNA libraries (Evans 
et al., 2008).  Oligonucleotide probes have become the most popular format in most DNA 
microarray facilities (Kreil et al., 2006). 
Because BRD is known to impact growth, performance, carcass quality, and 
profitability, we conducted an experiment to identify genes that are differentially 
expressed in economically important tissues in chronic vs. healthy heifers following a 63-




METHODS AND MATERIALS 
 The experimental protocol was approved by the Oklahoma State University 
Institutional Animal Care and Use Committee.   
Animals 
 Three hundred sixty high-risk heifers (initial BW = 248 ± 14 kg) were purchased 
from multiple auction barns in Kentucky and delivered to the Willard Sparks Beef 
Research Feedlot (WSBRF), Stillwater, OK.  The heifers were individually identified 
and ear-notched to test for persistent infection with bovine viral diarrhea virus (BVDV) 
as described by Fulton et al. (2006) in Kentucky before shipment.  However, persistently 
infected heifers (n = 1) were not removed from the group until after arrival at the 
WSBRF.  Upon arrival, heifers were weighed and given ad libitum access to prairie hay.  
Within 24 hours of arrival heifers were processed.  Initial processing consisted of 
administration of a modified live viral respiratory vaccine (IBRV-BVDV Type 1 and 2-
PI3V-BRSV, Pyramid 5, Fort Dodge Animal Health, Overland Park, KS), a 7-way 
Clostridial bacterin/toxoid (Vision 7, Intervet/Schering-Plough Animal Health, DeSoto, 
KS), and dewormed with a moxidectin (Cydectin, Fort Dodge Animal Health, Overland 
Park, KS).  All heifers were implanted with estradiol and trenbalone acetate (Component 
TE-G, Elanco Animl Health, Indianapolis, IN).  Seven days after initial processing 
heifers were re-vaccinated with Pyramid 5 (Fort Dodge Animal Health). 
Once moved to assigned pens heifers were offered prairie hay and 1% of BW of a 
diet consisting of (DM basis) 45% dry rolled corn, 15% corn WDGS, 17.5% ground 
alfalfa hay, 17.5% ground grass hay, and 5% pelleted supplement [69.6% wheat 




copper sulfate, 0.1% manganous oxide, 0.06% vitamin A (30,000 IU/g), 0.04% vitamin E 
(50%) and 0.25% Rumensin 80 (Elanco Animal Health, Indianapolis, IN)].   
 Heifers were observed daily for signs of BRD by trained professionals as 
described by Step et al. (2008).  Briefly, evaluators used criteria based on the DART 
system (Pharmacia Upjohn Animal Health, Kalamazoo, MI) with modifications.  The 
major observable signs were depression, appetite, respiratory signs, and rectal 
temperature.  The heifers were assigned severity scores ranging from 1 to 4 where a 1 
was assigned for mild symptoms, 2 for moderate, 3 for severe and 4 for moribund.  The 
criterion for antimicrobial treatment was determined by using a combination of the visual 
observation ranking and rectal temperature.  Animals that had a severity score of 1 and 2 
had to have a rectal temperature of 40˚C or greater before an antimicrobial treatment was 
administered.  If a heifer had a severity score of 3 or 4 she was automatically treated with 
an antimicrobial.  The first antimicrobial treatment was tilmicosin (Micotil 300, Elanco 
Animal Health, Greenfield, IN) at a dosage rate of 10 mg/kg BW.  If a second treatment 
was required (a minimum of 120 hours after first injection for severity scores of 1 or 2; 
72 hours for 3 or 4), the antimicrobial used was enrofloxacin (Baytril 100, Bayer Corp, 
Shawnee Mission, KS) at a dosage rate of 10 mg/kg BW.  If a third treatment was needed 
(at least 48 hours after second treatment) ceftiofur hydrochloride (Excenel RTU, Elanco 
Animal Health) was used at a dosage rate of 2.2 mg/kg BW.  Forty-eight hours after the 
third treatment heifers were given another treatment with ceftiofur HCl.  When visual and 
temperature criteria were not met, no antimicrobial was given, and both treated and non-




recorded at the time of treatment and on d 63 to determine ADG during the 
preconditioning period. 
 After 63 days on feed, five heifers from the “healthy” (HLTH) group and five 
heifers from the “chronic” (CHR) group were chosen at random to be biopsied from the 
LM and SCF.  Healthy was defined as an animal that had never been pulled for signs of 
BRD or any other disease and were never treated with an antimicrobial for clinical signs 
of BRD.  Chronic was defined as heifers that had been identified as morbid and received 
antimicrobial treatment three times, were identified as being sick a fourth time, and lost 
BW during the previous 21 days.  After the heifers were identified as CHR they were 
moved from their home pen to a chronic pen where heifers were placed on the growing 
diet described above and given free-choice prairie hay for the duration of the receiving 
period (total 63 days).   
On d 63, biopsies were taken from the SCF and LM.  After using a local 
anesthetic and cutting through the skin, thumb forceps were used to raise the SCF and a 
sample (approximately 100 mg) was removed with scissors.  Biopsies for LM tissue 
followed the procedure described by Winterholler et al. (2008).  Biopsy samples were 
immediately snap frozen in liquid nitrogen, and stored frozen (-80˚C) until further 
processing. 
RNA extraction 
 RNA was extracted from both tissues using TRIzol following the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA).  Briefly, ~0.2 g of tissue was homogenized in 1 mL 
of TRIzol.  The homogenate was clarified by centrifuging at 12,000 × g for 10 min at 




protein.  Chloroform (0.2 mL) was added and incubated at room temperature for 10 min.  
Separation was done by centrifugation at 12,000 × g for 15 min at 4˚C.  The aqueous 
phase (RNA) was removed and precipitated out with isopropanol.  Ethanol (75%) was 
included to wash the pellet and then the pellets were dissolved in DEPC water.   
 A 1.5% agarose gel with ethidium bromide was used to determine the quality of 
the RNA.  The quantity was determined using a Nanodrop™ ND-100 spectrophotometer 
(NanoDrop Technologies, Willington, DE). 
Microarray 
 A long oligo, whole bovine array from the Bovine Microarray Consortium (Elsik, 
2006 http://animalsciences.missouri.edu/animalgenomics/bomc.php) was used to 
randomly compare HLTH to CHR heifers.  Total RNA (500 ng) was used in an 
EPICENTRE TargetAMP™ 1-round aminoallyl-aRNA amplification (EPICENTRE 
Biotechnologies, Madison, WI) protocol with a few modifications.  In the in vitro 
transcription of aminoallyl-aRNA step, 6.0 µL of aminoallyl-UTP per reaction instead of 
2.4 µL per reaction was added.  Alexa Fluor™ 546 tagged the reference sample (HLTH) 
and Alexa Fluor™ 647 tagged the test sample (CHR). 
 Slides were pre-hybridized by being rinsed in 0.1% sodium dodecyl sulfate (SDS) 
for 5 min, rinsed in sterile double distilled water (ddH2O) for 15 s, and immediately 
dried for 2 min using a slide centrifuge.  The slides were placed into a 50 mL conical vial 
that contained warmed (48˚C) commercial pre-hybridized buffer (BlockIT Microarray 
Blocking Solution, TeleChem Int., Sunnyvale, CA) and incubated at 48˚C for 4 h.  The 





 The entire 80 µL hybridized sample with dye and buffer was placed under a 24 × 
60 mm lifterslip (Erie Scientific, Portsmouth, NH) on the warmed (hybridized) slide 
(42˚C).  The slides were placed into a hybridization chamber and maintained overnight 
(20 h) in a 42˚C hybridization oven. After hybridization the post-hybridization wash steps 
included disassembling the chamber by immersing the slide and cover slip into a 50 mL 
conical tube with 2X sodium chloride/sodium citrate (SSC)/0.2 SDS (42˚C).  The slide 
was transferred to another conical with 2X SSC/0.2 SDS (42˚C) for 15 min with gentle 
agitation.  It was then transferred to a 2X SSC wash for 15 min at room temperature with 
gentle agitation.  The final wash was in a 0.2X SSC for 15 min at room temperature with 
gentle agitation.  The slide was then spun dry for 1 min using a slide centrifuge. 
Analysis of slides 
The slides were scanned at two wavelengths (Alexa 555 and Alexa 647) using a 
ScanArray™ Express confocal laser scanner (PerkinsElmer Life Sciences Inc., Boston, 
MA) at a pixel size resolution of 10 microns with the resulting image saved as a 16 bit 
TIFF image.  The image was placed into a commercial software package (GenePix™ Pro 
5.0, Axon Instruments Inc., Union City, CA) used to analyze spot intensity while 
subtracting local background.  The GenePix Pro results (GPR) were then placed into the 
GenePix AutoProcessor (GPAP 3.2) website from the Oklahoma State University 
Department of Biochemistry and Molecular Biology (http://darwin.biochem.Okstate. 
edu/gpap32/). The R-project statistical analysis was accomplished while using the 
Bioconductor and LIMMA packages where background correction was performed using 
Robust Multi-array Average (RMA) algorithm (Allison et al., 2006). A moderated T-test 




(expression ratio = log2(647intensity/546intensity)) and P-value, obtained from the 
moderated t-statistic after false discovery rate using the Benjamini and Hochberg method 
(Benjamini and Hochberg, 1995).  Significance level for differentially expressed oligos 
was set at ‘t’>2 (absolute value), a M-value>+0.9 or <-0.9 (which represents a fold 
change of >1.87 or <-1.87), and a P-value < 0.01. 
 The significant gene sequences were placed into multiple different software 
programs to determine the ontology of the differentially expressed oligos; Entrez Gene 
(http://www.ncbi.nlm.nih.gov), Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov/), and Genome Functional Integrated 
Discoverer (GFINDer) (http://www.medinfopoli.poli.it/GFINDer/). 
Validation of microarray 
 Total RNA (1 µg) was used to make cDNA with the QuantiTect® Reverse 
Transcription kit following the manufacturer’s protocol (QIAGEN Inc., Valencia, CA).  
The cDNA was then used as the template for real-time PCR.  Ten genes were selected to 
be validated (twelve samples); three were up-regulated and three down-regulated in each 
tissue type with two genes that were differently expressed in both tissues (Table 1).  The 
primers were designed using a sequence designed from Primer 3 
(http://frodo.wi.mit.edu/) and Integrated DNA Technologies (IDT, 
http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/) software.  The primer 
sequences, temperatures, and product size are described in Table 1. 
 An iCycler real-time detection system (Bio-Rad Laboratories, Inc., Herules, CA) 
was used along with SYBR Green Supermix to determine gene expression. 18S was used 




dilutions.  Thermal cycling conditions were 95˚C for 30 s, followed by 40 cycles of 95˚C 
for 15 s, variable annealing temperatures for 30 s, and 72˚C for 30 s.  This was followed 
by a melt curve analysis by increasing the reaction to 95˚C for 1 min, 55˚C for 1 min, and 
then increasing the temperature by 0.5˚C from 55˚C to 94.5˚C.  The samples were 
analyzed in triplicate. 
 Gene expression changes were calculated as described by Livak and Schmittgen 
(2001).  A cycle threshold (CT) was assigned to each of the samples.  A ∆CT value was 
calculated for each replicate by subtracting 18S rRNA CT from the corresponding gene 
samples CT.  An average of the replicates was utilized to compare the gene expression 
levels to determine directionality.  Fold change was calculated by determining the ∆∆CT.  
This was accomplished by subtracting the lowest expression level from the highest and 
plugged into the formula: fold change = 2-∆∆CT. 
Ingenuity Pathway Analysis 
 Ingenuity Pathways Analysis (IPA) (Ingenuity® Systems, 
http://www.ingenuity.com) was utilized to identify the most relevant biological 
mechanisms, pathways and functions of differentially expressed genes.  IPA enables the 
visualization and exploration of gene interactions and relies on the most currently known 
relationships among human, mouse, and rat genes and proteins.  All differentially 
expressed genes and M-values were imported into the program and the maps were 








 The experiment was a completely randomized design.  Data were analyzed using 
the PROC MIXED procedure of SAS (SAS Inst., Inc., Cary, NC).  Results are discussed 




 To validate our experimental model treatment records and growth variables were 
recorded for each heifer.  On average, day to first, second, and third antimicrobial 
treatment for chronic heifers was 2 ± 1.5, 8 ± 2.2, and 13 ± 5.3 from arrival, respectively; 
the range of treatment days was 0 to 23.  The average day that heifers were moved to the 
chronic pen was 32 ± 13 days on feed.  From d 0 to 63, ADG for HLTH heifers was 1.58 
± 0.59 kg/d, whereas ADG for CHR heifers was 0.61 ± 0.69 kg/d. 
Microarray 
 Microarray results showed that there were 186 differentially expressed genes in 
the LM with 43 up-regulated and 143 down-regulated.  Up-regulated indicates that the 
gene (spot intensity) was more highly expressed in CHR than HLTH.  Down-regulated 
indicates that the gene was less highly expressed in CHR in relation to HLTH.  In the 
SCF there were 121 differentially expressed genes; 77 were up-regulated and 44 down-
regulated.  Up-regulated genes were more prevalent in SCF, whereas the number of 
down-regulated genes was greater in LM. 
 After identifying the differently expressed oligos, sequences were run through the 




Biotechnology Information (NCBI) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The oligos 
were identified and given an accession code (Entrez gene ID) to determine ontology. 
Ontology consists of molecular function, biological process, and cellular components.  
For the purpose of this experiment we used the molecular function and biological process 
for general groupings of ontologies.  Within the LM the largest percentage of differently 
expressed genes were in the metabolic process category, followed by binding, cellular 
process, and proteolysis (Table 2).  In LM, chronic animals showed an increase in 
expression of genes that regulate protein modification/proteolysis.  In SCF chronic 
animals had an increase in expression of genes that modulate transcription, fatty acid 
metabolism, multi-cellular processes, and apoptosis.  In CHR animals there was a 
decrease in LM for genes involved in metabolic activities and in SCF for immunological 
function and translation.  Also, within both tissues CHR heifers had a decrease in 
expression of genes involved in transport of nutrients and binding.  In SCF the largest 
percentage of differentially expressed genes was in the binding and immunological 
category, followed by multicellular processes and proteolysis (Table 2).  Grouped by 
ontology, Table 3 shows the individual differentially expressed genes in LM, and Table 4 
shows the individual differentially expressed genes in SCF.  There were two genes that 
were shown to be significantly differentially expressed in both tissues.  Ribosomal 
protein S19 binding protein 1 (RPS19BP1) was down-regulated and Homeobox A5 
(HOXA5) was up-regulated in both tissues. 
RT-PCR 
 75% of the genes that were chosen for validation showed the same directional 




of the 12 showed opposite directional tendencies.  Those genes were fatty acid binding 
protein 5 (FABP5), cathelicidin 5 (CATHL5), and RPS19BP1.  All three of these genes 
were down-regulated in the microarray, FABP5 and RPS19BP1 in LM and CATHL5 in 
SCF.  Figure 1 shows the genes that were validated and the directional tendencies of both 
the microarray and RT-PCR results. 
 In LM, fold expression of 26S tended to be greater (P = 0.10; Figure 2) in CHR 
heifers compared with HLTH heifers.  Haptoglobin (HP) expression in SCF was greater 
(P = 0.03) for HLTH compared with CHR heifers (Figure 3).  Although directional 
changes were similar to the microarray, differences among treatments were not observed 
(P > 0.10) for the remaining genes used for validation via RT-PCR. 
 
DISCUSSION 
In the present experiment, several genes involved in the ubiquitin pathway were 
up-regulated in chronic heifers (Figure 4).  In human and mice experiments it has been 
shown that when the ubiquitin pathway is over-stimulated it leads to chronic muscle 
wasting and atrophy (Cao et al., 2005).  Muscle is not only used in contractile functions, 
but when stress occurs protein stored in muscle is mobilized as a source of amino acids 
for energy (Cao et al., 2005).  As summarized by Cao et al. (2005), the ubiquitin-
proteosome pathway contributes to the majority of intracellular proteolysis in muscle.  
This system works by linking chains of polypeptide cofactor ubiquitins onto proteins to 
mark them for degradation by the 26S proteosome.  The three enzymes in the chain are 
E1, E2, and E3.  E1 are the ubiquitin-activating enzymes; E2 are the ubiquitin-




several dozen E2 in a cell and more than a thousand E3 (Cao et al., 2005).  Multiple E3, 
which is the final step in the process that tags the protein for cleavage, allows for multiple 
routes by which this pathway can be activated and lead to muscle wasting.  Tisdale 
(2007) suggested that the ubiquitin-protease pathway has three main E3 that are 
catabolically up-regulated in skeletal muscle in response to stress; muscle RING finger 1 
(MuRF1), muscle atrophy F-box (MAFbx), also called atrogin, and E3α-II.   
 In the present experiment, genes that were up-regulated in LM involved in the 
ubiquitin-protease pathway were autocrine motility factor receptor (AMFR), Fas 
(TNFRSF6) associated factor 1 (FAF1), ankyrin repeat and SOCS box containing 2 
(ASB2), 26S proteosome (26S), proteasome (prosome, macropain) 26S subunit, ATPase, 
1 (PSMC1), and ATPases (both ATP2B2 and ATP8B2) (Figure 5).  These genes are 
connected in both function and within pathways that include heat shock protein 70 
(Hsp70) and down-regulated genes toll interacting protein (TOLLIP) and hypoxia-
induced factor 1, alpha subunit (basic helix-loop-helix transcription factor; HIF1A).  
Chiu et al. (2008) showed that AMFR exhibits E3 ligase activity which alters cellular 
adhesion, proliferation, motility, and apoptosis.  In humans, AMFR has been observed to 
be expressed in numerous cancers primarily in the lung, esophagus, stomach, colon, 
rectum, liver, and skin (Chiu et al., 2008).  FAF1 is a protein that has multi-ubiquitin-
related domains and several different functions.  FAF1 is a type of E3 protein and in 
humans acts as a tagging site for apoptosis and directly affects NF-κB activation through 
IκK cleavage (Song et al., 2005).  FAF1 in humans acts as a binding protein for the 
ATPase domain Hsp70 that activates immunoprecipitation (Kim et al., 2005).  The 




up-regulated in LM in the present experiment (Figure 2).  Changes in expression of 
several genes in the ubiquitin-protease pathway in CHR heifers in the present experiment 
may suggest that severe or chronic BRD may lead to muscle wasting and atrophy, which 
could have long-term negative effects on animal growth and carcass quality.  
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 (NDUFA1), an 
ubiquitione, is initially activated by hepatocyte nuclear factor 4, α (HNF4A), which was 
shown through IPA analysis to increase expression of many genes that were differentially 
expressed in the array of the present experiment (Figure 6).  ASB2 is predominantly 
expressed in muscle and if observed to be overexpressed results in inhibition of myoblast 
differentiation (McDaneld and Spurlock, 2008).  ASB2, primarily the SOCs box, 
parallels F-box and WD repeat domain containing 12 (FBXW12; Hershko and 
Ciechanover, 1998).  Other genes up-regulated involved with the ubiquitin pathway 
included RWD domain containing 1(RWDD1), sumo1 activating enzyme subunit 1 
(SAE1), and ubiquitin specific peptidase 15 (USP15).  FBXW12, RWDD1, and USP15 
are ubiquitone E3, and SAE1 is an E1. 
 Hypoxia-induced factor 1, α subunit (HIF1A) stimulates angiogenesis which 
increases the establishment of new blood vessels.  However, in humans it has been shown 
that HIF1A, when bound to von Hippel-Lindau (VHF), results in ubiquitin tagging and 
ultimate degradation (Petroski, 2008).  HIF1A was down-regulated in LM in the present 
experiment. 
 In SCF, Ingenuity software revealed several up-regulated genes and down-
regulated genes involved with HNF4A (Figure 6).  Hepatocyte nuclear factor 4, α has 




insulin resistance (Love-Gregory and Permutt, 2007).  Diabetes and improper growth and 
development of the hepatic system occur with mutations in this transcription factor 
(Velho and Froguel, 1998; Maestro et al., 2007).  Beta-estradiol was also a central hub 
within the SCF Ingenuity pathway that showed effects involving differentially expressed 
genes (Figure 6).  Genes that were up-regulated included calponin 1, basic, smooth 
muscle (CNN1), and ankylosis, progressive homolog (ANKH), and down-regulated 
included chromosome 9 open reading frame 16 ortholog (C11ORF10) and wingless-type 
MMTV integration site family, member 11 (WNT11).  The down-regulation of CNN1 
could be a potential trigger for the activities of HNF4A (Figure 6).    
Genes that affect hepatic fibrosis and hepatic stellate cell (HSC) activation were 
also up-regulated and could be another potential cause of decreases in growth and 
performance of CHR animals.  Hepatic stellate cells have a central role in hepatic 
fibrogenesis (Friedman, 2000).  Hepatic fibrogenesis is scarring of the liver that can come 
from a variety of different factors like necrosis due to stress and lymphocyte activation.  
We observed up-regulation of collagens, COL1A2 and COL1A1 in LM and SCF in the 
present experiment.  The collagens are affected by Smad (primarily Smad3) which leads 
to increases in both COL1A1 and COL1A2.   
In conclusion, decreasing the detrimental effects of an over-activated ubiquitin-
proteosome pathway could decrease the instances of muscle wasting in heifers treated 
multiple times for BRD.  However, appropriate base-line expression levels should be 
determined along with potential side-effects of slowing this process due to the need for 
certain stages of transcription and cellular activation.  In addition, greater growth rates in 




and immunological functions, and potential links between a pathogen insult and changes 
in gene expression should be further explored.  Use of the whole genome microarray was 
a beneficial tool to look at differences in chronic animals versus animals that were 
considered to be healthy.  This approach allowed us to identify pathways that when 
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Table 1: RT-PCR primers used in the validation step.     
  





26S LM Forward 5’-CAGTGATGAAGGTGGAAAAGG-3’ 184 59 506238 
  Reverse 5’-GCGGACCATAGAGAATGACC-3’    
CADH1 SCF Forward 5’-CGTTTCCTAAGTCGCTGGTC-3’ 272 55.5 282637 
  Reverse 5’-GGGCTTGTTGTCATTCTGGT-3’    
CATHL5 SCF Forward 5’-AGGACGATGAGAACCCAAAC-3’ 112 58 282167 
  Reverse 5’-CCACACACTCTTTCAGCAGC-3’    
CXCL3 LM Forward 5’-GCCAAACCGAAGTCATAGCC-3’ 249 58 613667 
  Reverse 5’-AAATAGTCCAGCACATCAAGTCC-3’    
FABP5 LM Forward 5’-ATGGCTCTGCGAAAAGTGG-3’ 145 59 281760 
  Reverse 5’-GCTGTGGTCTCTTCAAACTTCTC-3’    
HOXA5 LM & 
SCF 
Forward 5’-GACCTCGTTTAGTGCCAATG-3’ 224 62-LM 768039 
 Reverse 5’-CAGAGTCACAGTTTTCGTCACAG-3’  61-SCF  
HP SCF Forward 5’-CGTGTGGGTTATGTGTCTGG-3’ 275 62 280692 
  Reverse 5’-GTGTCGTCTTCCTTGTCGTG-3’    
ITGB8 SCF Forward 5’-CAGTTTCACCATACATTAGCATCC-3’ 244 58 3696 
  Reverse 5’-AGCCTCTTTTCGCCATCC-3’    
RPS19BP1 LM & 
SCF 
Forward 5’-CAGGAGAACCAGGAAGAAACC-3’ 152 62-LM 509108 
 Reverse 5’-TAGAACCCGAAGCCTACCC-3’  61-SCF  
TRA1 LM Forward 5’-TCTTGCTGTGGTTTTGTTTG-3’ 238 58 282646 
  Reverse 5’-TTGTTCTTCCTCGTCTGTTCC-3’    
 
 
Table 2:  Ontological groupings for LM and SCF.       
Category % LM1 % Up- LM2 % Down-LM3 % SCF4 % Up-SCF5 % Down-SCF6 
Proteolysis 11.9 16.1 10.3 13.9 8.6 20.0  
Apoptosis 2.8 6.5 1.3 1.5 2.9 -- 
Binding 14.7 6.5 17.9 18.5 17.1 20.0 
Cellular processes 11.9 9.7 12.8 10.8 14.3 6.7 
Translation 5.5 9.7 3.8 6.2 2.9 10.0 
Transcription 7.3 6.5 7.7 4.6 8.6 -- 
Metabolism 25.7 22.6 26.9 9.2 11.4 6.7 
Nutrient Transport 8.3 6.5 9.0 12.3 11.4 13.3 
Multi-cellular process 0.9 3.2 -- 4.6 8.6 -- 
Immune response 7.3 9.7 6.4 18.5 14.3 23.3 
Structural component 3.7 3.2 3.8 -- -- --  
1Percentage of differentially expressed genes within category in LM. 
2Percentage of genes up-regulated in LM. 
3Percentage of genes down-regulated in LM. 
4Percentage of differentially expressed genes within category in SCF. 
5Percentage of genes up-regulated in SCF. 






Table 3: Differentially expressed genes in LM grouped based on ontology – molecular 
function and biological process.  
 Entrez ID Gene Name M value 
Proteolysis/protein modification/catabolism 
 541216 RWDD1 RWD domain containing 1 [Bos taurus] 1.38 
 539244 ASB2 ankyrin repeat and SOCS box containing 2 [Bos taurus] 1.96 
 515109 TIMM8a translocase of inner mitochondrial membrane 8 homolog A (yeast) [Bos taurus] -1.50 
 507222 TMEM208 transmembrane protein 208 [Bos taurus] 2.81 
 618428 CACYBP calcyclin binding protein [Bos taurus] -2.89 
 505512 SAE1 sumo1 activating enzyme subunit 1 [Bos taurus] 2.23 
 404101 BMPR1A bone morphogenetic protein receptor, type IA [Bos taurus] -1.22 
 506238 PSMC1 proteasome (prosome, macropain) 26S subunit, ATPase, 1 [Bos taurus] 3.51 
 510524 CTSH cathepsin H [Bos taurus] -2.26 
 451586 UBE4A ubiquitination factor E4A (UFD2 homolog, yeast) [Pan troglodytes] -1.95 
 789588 LOC789588 similar to chromosome 9 open reading frame 3 [Bos taurus] -1.46 
 520170 UCHL3 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) [Bos taurus] -2.10 
 518834 UBA6 ubiquitin-like modifier activating enzyme 6 [Bos taurus] -1.76 
Apoptosis 
 282646 TRA1 tumor rejection antigen (gp96) 1 [Bos taurus] -3.16 
 533406 PDCD6IP programmed cell death 6 interacting protein [Bos taurus] 1.28 
 531770 FAF1 Fas (TNFRSF6) associated factor 1 [Bos taurus] 3.43 
Cellular process 
 281950 NRXN1 neurexin 1 [Bos taurus] -2.37 
 528265 SNX3 sorting nexin 3 [Bos taurus] -1.21 
 281798 GNRHR gonadotropin-releasing hormone receptor [Bos taurus] -1.21 
 511812 GNG11 guanine nucleotide binding protein (G protein), gamma 11 [Bos taurus] -1.00 
 506708 RADIL Rap GTPase interactor [Bos taurus] 1.24 
 287018 GNG guanine nucleotide binding protein (G protein), gamma 5 [Bos taurus] -1.65 
 532389 MRPL44 mitochondrial ribosomal protein L44 [Bos taurus] -2.74 
 511080 CCDC11 coiled-coil domain containing 111 [Bos taurus] -1.84 
 404159 TXNDC17 thioredoxin domain containing 17 [Bos taurus] -2.21 
 504519 CAP1 CAP, adenylate cyclase-associated protein 1 (yeast) [Bos taurus] 1.42 
 287016 H2AFZ H2A histone family, member Z [Bos taurus] -1.64 
 445425 TKT transketolase [Bos taurus] 4.02 
 280939 TEK TEK tyrosine kinase, endothelial [Bos taurus] -1.59 
Translation 
 504754 MTRF1 mitochondrial translational release factor 1 [Bos taurus] 2.06 
 510729 TRPT1 tRNA phosphotransferase 1 [Bos taurus] 1.77 
 404190 RPL27A ribosomal protein L27a [Bos taurus] 2.06 
 527129 SRP9 signal recognition particle 9kDa [Bos taurus] -1.29 
 615845 GATC glutamyl-tRNA (Gln) amidotransferase, subunit C homolog (bacterial) [Bos taurus] -1.97 
 520875 EEF1B2 eukaryotic translation elongation factor 1 beta 2 [Bos taurus] -0.99 
Trascription 
 782993 RPL7 ribosomal protein L7 -2.30 
 282711 EPAS1 endothelial PAS domain protein 1 [Bos taurus] 1.28 
 515561 ZNF462 zinc finger protein 462 -2.39 
 614212 LMO4 LIM domain only 4 [Bos taurus] -2.14 
 540959 CRTC2 CREB regulated transcription coactivator 2 [Bos taurus] -2.17 
 616523 SLMO2 slowmo homolog 2 (Drosophila) [Bos taurus] 1.35 
 513254 PEBP4 phosphatidylethanolamine-binding protein 4 [Bos taurus] -1.70 
 508005 EXOSC9 exosome component 9 [Bos taurus] -2.56 
Metabolism 
 613932 PLD3 phospholipase D family, member 3 [Bos taurus] -2.33 
 281615 ALDH1A1 aldehyde dehydrogenase 1 family, member A1 [Bos taurus] 2.14 




 512468 GCLC glutamate-cysteine ligase, catalytic subunit [Bos taurus] -1.91 
 508712 CCBL2 cysteine conjugate-beta lyase 2 [Bos taurus] -1.56 
 511901 LOC511901 similar to H1 histone family, member X [Bos taurus] -2.38 
 281814 HIF1A hypoxia-induced factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
  [Bos taurus] -1.96 
 541108 LOC541108 similar to histone cluster 2, H2aa4 [Bos taurus] -1.52 
 507631 TYMS thymidylate synthetase [Bos taurus] -2.21 
 508131 ZNF836 zinc finger protein 836 [Bos taurus] -2.30 
 615692 SAP18 Sin3A-associated protein, 18kDa [Bos taurus] 1.15 
 281760 FABP5 fatty acid binding protein 5 [Bos taurus] -1.51 
 616931 NUDT10 nudix (nucleoside diphosphate linked moiety X)-type motif 10 [Bos taurus] -1.40 
 504287 SOAT1 sterol O-acyltransferase 1 [Bos taurus] -1.82 
 281400 PHYH phytanoyl-CoA 2-hydroxylase [Bos taurus] 1.84 
 615390 ACAA2 acetyl-Coenzyme A acyltransferase 2 [Bos taurus] 3.34 
 281785 GLUD1 glutamate dehydrogenase 1 [Bos taurus] -1.34 
 532512 POR cytochrome P450 reductase [Bos taurus] -2.24 
 282318 PPP1CC protein phosphatase 1, catalytic subunit, gamma isoform [Bos taurus] -1.61 
 618278 COMT catechol-O-methyltransferase [Bos taurus] -2.27 
 614215 DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 [Bos taurus] -2.47 
100138017 LOC100138017 similar to protein tyrosine phosphatase, receptor type, A [Bos taurus] -2.77 
 614196 LACTB lactamase, beta [Bos taurus] 1.95 
 282199 COX6A1 cytochrome c oxidase subunit Via polypeptide 1 [Bos taurus] -2.15 
 538060 LOC538060 similar to Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
  dehydrogenase, type II) [Bos taurus] -3.03 
 533020 CBR4 carbonyl reductase 4 [Bos taurus] -2.54 
 540559 LANCL1 LanC lantibiotic sythetase component C-like 1 (bacterial) [Bos taurus] 1.49 
 281090 COX4 cytochrome c oxydase subunit 4 [Bos taurus] 3.69 
Binding 
 767990 ATXN10 ataxin 10 [Bos taurus] -2.42 
 617531 LOC617531 similar to Calcium and integrin binding family member 2 [Bos taurus] -1.93 
 407176 KCNMB1 potassium large conductance calcium-activated channel, subfamily M, beta 
  member 1 [Bos taurus] 1.77 
 507319 EFNA1 ephrin-A1 [Bos taurus] -1.78 
 520939 LOC520939 similar to Krueppel-like factor 2 (Lung krueppel-like factor) [Bos taurus] -1.62 
 532571 WWC2 WW and C2 domain containing 2 [Bos taurus] -2.40 
 538880 CPEB2 cytoplasmic polyadenylation element binding protein 2 [Bos taurus] -2.14 
 613634 LSM4 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) [Bos taurus] -1.76 
 614921 NUTF2 nuclear transport factor 2 [Bos taurus] -1.62 
 507541 AMFR autocrine motility factor receptor [Bos taurus] 2.43 
 513331 PHF11 PHD finger protein 11 [Bos taurus] -0.97 
 506534 CNPY2 canopy 2 homolog (zebrafish) [Bos taurus] -2.95 
 786844 MXRA5 matrix-remodelling associated 5 [Bos taurus] -1.45 
 526027 SPTBN1 spectrin, beta, non-erythrocytic 1 [Bos taurus] -3.26 
 533233 APC adenomatous polyposis coli [Bos taurus] -1.16 
 509108 RPS19BP1 ribosomal protein S19 binding protein 1 [Bos taurus] -1.92 
Transport 
 506738 NUP155 nucleoporin 155kDa [Bos taurus] -2.17 
 510872 NCBP2 nuclear cap binding protein subunit 2, 20kDa [Bos taurus] -1.82 
 9444 QKI quaking homolog, KH domain RNA binding (mouse) [Homo sapiens] -1.04 
 280813 HBB hemoglobin, beta [Bos taurus] -1.53 
 534150 OPTN optineurin [Bos taurus] -1.79 
 327673 NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa [Bos taurus] 0.94 
 616979 RAB31 RAB31, member RAS oncogene family [Bos taurus] -1.90 
 528100 SERP1 stress-associated endoplasmic reticulum protein 1 [Bos taurus] -1.96 





Multicellular organismal process 
 768039 HOXA5 homeobox A5 2.28 
Structural molecule activity 
 615087 TUBB tubulin, beta [Bos taurus] -1.08 
 282188 COL1A2 collagen, type I, alpha 2 [Bos taurus] 1.98 
 526516 HOOK2 hook homolog 2 (Drosophila) [Bos taurus] -1.88 
 407121 NEB nebulin [Bos taurus] -2.13 
Immunological process 
 613667 CXCL3 chemokine (C-X-C motif) ligand 3 [Bos taurus] 2.69 
 511603 PDIA5 protein disulfide isomerase family A, member 5 [Bos taurus] -1.14 
 286793 PRDX2 peroxiredoxin 2 [Bos taurus] -1.00 
 618411 LILRA4 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain),  
  member 4 [Bos taurus] -2.07 
 511486 TRAα T cell receptor, alpha [Bos taurus] -2.11 
 510798 TNFRSF10A tumor necrosis factor receptor superfamily, member 10a [Bos taurus] 1.72 
 652614 LOC652614 similar to HLA class I histocompatibility antigen, A-11 alpha chain precursor  
  (MHC class I antigen A*11) [Bos taurus] 3.30 
 528862 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 [Bos taurus] -0.94 
 
Unknown ontology 
 533177 SCARB2 scavenger receptor class B, member 2 [Bos taurus] -2.20 
 506530 SSR signal sequence receptor, beta (translocon-associated protein beta) [Bos taurus] -2.47 
 505336 EPN2 epsin 2 [Bos taurus] -2.19 
 511763 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein [Bos taurus] -1.04 
 781257 MTCH1 mitochondrial carrier homolog 1 (C. elegans) [Bos taurus] -1.00 
 510842 LPCAT4 lysophosphatidylcholine acyltransferase 4 [Bos taurus] -2.43 
 509503 C19H17ORF39 chromosome 17 open reading frame 39 ortholog [Bos taurus] -1.53 
 533820 MEGF9 similar to multiple EGF-like-domains 9 [Bos taurus] -2.44 
 715086 LOC715086  similar to serine/threonine kinase 2 [Macaca mulatta] -1.92 
 509776 WDR32 WD repeat domain 32 [Bos taurus] -2.15 
 539480 TOLLIP toll interacting protein [Bos taurus] -1.88 
100153256 LOC100153256 similar to Serine/threonine-protein phosphatase 6 (PP6) [Sus scrofa] 1.35 
 512321 LOC512321 similar to missing oocyte CG7074-PA [Bos taurus] -2.53 
 512327 DHX15 DEAH (Asp-Glu-Ala-his) box polypeptide 15 [Bos taurus] -2.24 
 533595 TLE2 transducin-like enhancer of split 2 (E(sp1) homolog, Drosophilia) [Bos taurus] -1.77 
100138550 LOC100138550 similar to FIP1-like 1 [Bos taurus] -2.38 
 616526 BET1 blocked early in transport 1 homolog (S. cerevisiae) [Bos taurus] -1.26 
 619052 LOC619052 similar to hCG2041454 [Bos taurus] -2.35 
 519736 RANBP10 RAN binding protein 10 [Bos taurus] -1.59 
 513309 GFM1 G elongation factor, mitochondrial 1 [Bos taurus] -1.38 
 785762 LOC785762 similar to prostaglandin F synthase-like 1 protein [Bos taurus] -3.05 
 475318 MFSD2 major facilitator superfamily domain containing 2 [Canis lupus familiaris] -2.03 
 519172 BLOC1S2 biogenesis of lysosomal organelles complex-1, subunit 2 [Bos taurus] -1.58 
 787566 LOC787566 similar to High mobility group protein B1 (High mobility group protein 1)  
  (HMG-1) [Bos taurus] -1.87 
 533520 OCIAD1 OCIA domain containing 1 [Bos taurus] -1.30 
 540910 SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,  
  subfamily e, member 1 [Bos taurus] -1.34 
 512094 ALKBH4 alkB, alkylation repair homolog 4 (E. coli) [Bos taurus] 2.52 
100126445 DGCR6L DiGeorge syndrome critical region gene 6-like [Bos taurus] -2.46 
 282658 ARPP-19 cAMP-regulated phosphoprotein, 19 kD[Bos taurus] -1.53 
100125763 LOC100125763 neuronal protein 3.1 [Bos taurus] -1.38 
 508569 LOC508569 similar to CG5913 CG5913-PA [Bos taurus] 2.55 
 508149 CCDC58 coiled-coil domain containing 58 [Bos taurus] -1.02 
 505238 RALB v-ral simian leukemia viral oncogene homolog B (ras relatated; GTP binding protein)  




 510412 GOLGA5 golgi autoantigen, golgin subfamily a, 5 [Bos taurus] -1.20 
 505320 ARIH2 ariadne homolog 2 (Drosophila) [Bos taurus] -1.62 
 506622 TMEM219 transmembrane protein 219 [Bos taurus] -1.80 
 617968 C25H7ORF47 chromosome 7 open reading frame 47 ortholog [Bos taurus] -1.92 
 613425 UROS uroporphyrinogen III synthase [Bos taurus] -1.18 
100153616 LOC100153616 similar to WHSC1L1 protein [Sus scrofa] -2.27 
dB EST ID Clone Name M value 
 2834671 1367982 MARC 7BOV Bos taurus cDNA 5', mRNA sequence 2.90 
 17191506 695769 MARC 6BOV Bos taurus cDNA 5', mRNA sequence -2.24 
 35786314 000829BEMN005742HT BEMN Bos taurus cDNA 5’, mRNA sequence -1.71 
 17179146 608349 MARC 6BOV Bos taurus cDNA 3’, mRNA sequence -2.13 
 41875419 A95041A FFB Bos taurus cDNA clone A9504 3’, mRNA sequence 3.01 
 48105736 LB03351.C21.1_L07 GC_BGC-33 Bos taurus cDNA clone IMAGE:8722521 -2.26 
 23533146 UMC-bend_0B02-018-e07 Day 16 Uterus from a non-pregnant animal bend Bos taurus  
  cDNA 3’, mRNA sequence -2.20 
 24791078 UMC-bcl_0A01-006-f02 Corpora Lutea (CL) Bos taurus cDNA 3’, mRNA sequence -1.44 
 24792343 UMC-bend_0B01-025-g11 Day 16 Uterus from a pregnant animal bend Bos taurus cDNA  
  3’, mRNA sequence -1.59 
 48110166 LB03418.C21_O13 GC_BGC-34 Bos taurus cDNA clone IMAGE:8660391 3’, mRN sequence -1.44 
 24792640 UMC-bend_0B02-024-g04 Day 16 Uterus from a pregnant animal bend Bos taurus cDNA  
  3’, mRNA sequence -2.42 
 43569254 LB01840.CR_P11 GC_BGC-18 Bos taurus cDNA clone IMAGE:8830909 5’, mRNA sequence -2.10 
 26586667 UMC-bcl_0A02-020-g02 Day 14 CL from a pregnant animal bcl Bos taurus cDNA 3’,  
  mRNA sequence -0.93 
 26586705 UMC-bcl_0A02-022-c06 14 CL from a pregnant animal bcl Bos taurus cDNA 3’,mRNA sequence -1.13 
 26587424 UMC-bcl_0B01-019-e10 14 CL from a non-pregnant animal bcl Bos taurus cDNA 3’,  
  mRNA sequence -2.31 
 53808734 C0009504K17.Q1KM13R KN510 Bos taurus rectum from E. coli unchallenged animals Bos  
  taurus cDNA clone C0009504K17 3’, mRNA sequence -2.28 
 26591099 UMC-bemiv_0B01-006-e09 Early Embryo In Vitro Produced bemiv Bos taurus cDNA 3’,  
  mRNA sequence -1.94 
 41933278 L97921A FNM Bos taurus cDNA L9792 3’, mRNA sequence -1.88 
 26591916 UMC-bemiv_0B02-008-h03 Pre-compaction morula in vitro produced bemiv Bos taurus  
  cDNA 3’, mRNA sequence -1.85 
 48104002 LB03326.C21.1_N17 GC_BGC-33 Bos taurus cDNA clone IMAGE:8712979 3’,mRNA sequence -2.00 
 26594691 UMC-bmix_0B02-004-d10 Day 16 Conceptus bmix Bos taurus cDNA 3’, mRNA sequence 2.71 
 26594691 UMC-bof_0A02-003-h02 Ovarian follicle recruited bof Bos taurus cDNA 3’, mRNA sequence -2.59 
 26595022 UMC-bof_0B02-001-h08 Ovarian follicle pre-ovulatory bof Bos taurus cDNA 3’,mRNA sequence 1.72 
 36369084 1602252 MARC 11BOV Bos taurus cDNA 3’, mRNA sequence -1.88 
 27655206 UMC-bcl_0A01-024-c08 Day 8 Corpus luteum bcl Bos taurus cDNA 3’, mRNA sequence -1.37 
 27655210 UMC-bcl_0A01-024-d02 Day 8 Corpus luteum bcl Bos taurus cDNA 3’, mRNA sequence -1.33 
 48108485 LB03411.c21_D17 GC_BGC-34 Bos taurus cDNA clone IMAGE:8657443 3’, mRNA sequence 1.82 
 35858054 010128BEMN061945HT BEMN Bos taurus cDNA 5’, mRNA sequence 1.33 
 27662271 UMC-bof_0A02-008-a10 Ovarian follicle pre-ovulatory bof Day 8 Corpus luteum bcl Bos  
  taurus cDNA 3’, mRNA sequence -2.31 
 48106176 LB03354.C21_P09 GC_BGC-33 Bos taurus cDNA clone IMAGE: 8723771 3’, mRNA sequence 0.92 
 28484716 UMC-bend_0B01-028-b04 Day 16 Uterus from a pregnant animal bend Bos taurus cDNA 3’  
  mRNA sequence -0.90 
 43575584 LB02731.CR.2_P19 GC_BGC-27 Bos taurus cDNA clone IMAGE:8621637 5’, mRNA sequence -1.36 
 28486526 UMC-bof-0B01-013-b07 Ovarian follicle recruited bof Bos taurus cDNA 3’, mRNA sequence 2.80 
 28666712 UMC-bemiv_0B01-029-b09 In virto derived blastocytes Day 8 bemiv Bos taurus cDNA 3’,  
  mRNA sequence -1.18 





Table 4: Differentially expressed genes in SCF grouped based on ontology – molecular 
function and biological process  
Entrez ID Gene Name M value 
Proteolysis/protein modification/catabolism 
 512484 TYK2 tyrosine kinase 2 [Bos taurus] -1.37 
 54954 FAM120C family with sequence similarity 120C [Homo sapiens] 0.96 
 614817 PSMG1 proteasome (prosome, macropain) assembly chaperone 1 [Bos taurus] -0.99 
 415116 PIM3 pim-3 oncogene [Homo sapiens] -1.63 
 538284 USP15 ubiquitin specific peptidase 15 [Bos taurus] 0.93 
 533874 PSMB3 proteasome (prosom, macropain) subunit, beta type, 3 [Bos taurus] -1.63 
 510796 LONP1 Ion peptidase 1, mitochondrial [Bos taurus] -0.91 
 528919 FBXW12 F-box & WD repeat domain containing 12 [Bos taurus] 1.04 
 280692 HP haptoglobin [Bos taurus] -0.97 
Apoptosis 
 444864 PEG3 paternally expressed 3 [Bos taurus] 1.89 
Cellular process 
 524821 SFT2DA SFT2 domain containing 1 [Bos taurus] 1.32 
 790411 LOC790411 endonuclease reverse transcriptase [Bos taurus] 1.04 
 281790 GNAI1 guanine nucleotide binding protein (G protein), α inhibiting activity polypeptide 1  
  [Bos taurus] 1.03 
 509717 CCNC cyclin C [Bos taurus] -1.66 
 514407 GMFG glia maturation factor, gamma [Bos taurus] -3.15 
 282637 CDH1 cadherin 1, type 1, E-cadherin (epithelial) [Bos taurus] 2.08 
 443076 C-MET growth factor receptor c-met [Ovis aries] 1.60 
Translation 
 23312 DMXL2 Dmx-like 2 [Homo sapiens] 0.98 
 286884 RPS29 ribosomal protein S29 [Bos taurus] -0.90 
 508948 RSL1D1 ribosomal L1 domain containing 1 [Bos taurus] -1.44 
 614579 MRPL14 mitochondrial ribosomal protein L14 [Bos taurus] -1.01 
Trascription 
 7003 TEAD1 TEA domain family member 1 (SV40 transcriptional enhancer factor)[Homo sapiens] 2.11 
 55274 PHF10 PHD finger protein 10 [Homo sapiens] 1.16 
 535026 CHD2 chromodomain helicase DNA binding protein 2 [Bos taurus] -1.38 
Metabolism 
 281103 CTGF connective tissue growth factor [Bos taurus] 1.67 
 281748 ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial [Bos taurus] 0.96 
 507988 CYP3A4 cytochrome P450, subfamily IIIA, polypeptide 4 [Bos taurus] -1.27 
 512112 AGPAT2 1-acylglycerol-3-phosphate-O-acyltransferase 2 (lysophosphatidic acid  
  acyltransferase, beta) [Bos taurus] -0.90 
 327696 SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa [Bos taurus] 1.26 
 505049 AMY2A amylase, alpha 2A (pancreatic) [Bos taurus] 1.26 
Binding 
 506275 WBP4 WW domain binding protein 4 (formin binding protein 21) [Bos taurus] 2.36 
 513047 ING1 inhibitor of growth family, member 1 [Bos taurus] -0.92 
 617552 CNKSR1 connector enhancer of kinase suppressor of Ras 1 [Bos taurus] -1.21 
 282196 CORO1A coronin, actin binding protein, 1A [Bos taurus] -1.89 
 534583 CNN1 calponin 1, basic, smooth muscle [Bos taurus] 1.84 
 538742 MIER1 mesoderm induction early response 1 homolog (Xenopus laevis) [Bos taurus] 1.34 
 536944 CLEC1A C-type lectin domain family 1, member A [Bos taurus] 1.24 
 532635 RCOR3 REST corepressor 3 [Bos taurus] 1.83 
 327666 SIRPA signal-regulatory protein alpha [Bos taurus] -1.20 
100139498 LOC100139498 similar to DNA replication licensing factor MCM9 (Mini-chromosome maintenance deficient 
   9) (hMCM9) (Mini-chromosome maintenance deficient domain containing protein 1)  [Bos taurus ] -1.92 
 613381 HN1 hematological and neurological expressed 1 [Bos taurus] -1.04 





 8411 EEA1 early endosome antigen 1 [Homo sapiens] 1.54 
 529929 DDX19A DEAD (Asp-Glu-Ala-As) box polypeptide 19A [Bos taurus] 0.95 
 282187 COL1A1 collagen, type I, alpha 1 [Bos taurus] 1.38 
 282523 SLC25A11 solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11  
  [Bos taurus] -1.15 
 286861 FTL ferritin, light polypeptide [Bos taurus] -0.90 
 511800 ANKH ankylosis, progressive homolog (mouse) [Bos taurus] 1.04 
100125922 RER1 RER1 retention in endoplasmic reticulum 1 homolog (S. cerevisiae) [Bos taurus] -3.30 
 26207 PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 [Homo sapiens] -1.19 
Multicellular organismal processes 
 3696 ITGB8 integrin, beta 8 [Homo sapiens] 1.76 
 22858 ICK intestinal cell (MAK-like) kinase [Homo sapiens] 2.54 
 768039 HOXA5 homeobox A5 [Bos taurus] 1.20 
Immunological response 
 282167 CATHL5 cathelicidin 5 [Bos taurus] -2.06 
 539220 AHSA1 AHA1, activator of heat shock 90kDa protein ATPase homolog1 (yeast) [Bos taurus] -1.19 
 615833 IFITM2 interferon induced transmembrane protein 2 (1-8D) [Bos taurus] -0.99 
 616015 C11H9orf16 chromosome 9 open reading frame 16 ortholog [Bos taurus] -1.14 
 767928 RBPJ recombination signal binding protein for immunoglobulin kappa J region [Bos taurus] -1.85 
 539674 TNFAIP1 tumor necrosis factor, alpha-induced protein 1 (endothelial) [Bos taurus] 1.94 
 613449 DCLK1 doublecortin-like kinase 1 [Bos taurus] 1.30 
 618530 C13H20ORF52 chromosome 20 open reading frame 52 ortholog [Bos taurus] -0.91 
 540085 GAB1 GRB2-associated binding protein 1 [Bos taurus] 1.03 
 529115 HIVEP1 human immunodeficiency virus type 1 enhancer binding protein 1 [Bos taurus 1.91 
 613288 WNT11 wingless-type MMTV integration site family, member 11 [Bos taurus] -1.08 
  ABL61276.1TCGR5 T cell receptor gamma c5 [Bos taurus] 1.04 
 
Unknown ontology 
100140540 LOC100140540 hypothetical protein LOC100140540 [Bos taurus] -0.91 
 782535 LOC782535 similar to Dmx-like 2 [Bos taurus] 0.98 
 767958 C29H11orf10 chromosome 11 open reading frame 10 ortholog [Bos taurus] -0.91 
 505843 LOC50583 hypothetical protein LOC505843 [Bos taurus] -1.81 
100157539 LOC100157539 similar to SWI/SNF-related matrix-associated actin-dependent regulator of  
  chromatin c2 [Sus scrofa] -1.92 
 338325 XIST X (inactive)-specific transcript [Bos taurus] 1.90 
 522372 SYF2 SYF2 homolog, RNA splicing factor (S. cerevisiae) [ Bos taurus] -1.32 
 768057 HIGD1A HIG1 domain family, member 1A [Bos taurus] -0.90 
 501569 RGD1564799 similar to transmembrane 4 superfamily member 10 [Rattus norvegicus] 1.35 
 781772 LOC781772 similar to RIKEN cDNA 2200001I15 [Bos taurus] 1.28 
 788792 FARSB phenylalanyl-tRNA synthetase, beta subunit [Bos taurus] -0.97 
 508905 ZRANB2 zinc finger, RAN-binding domain containing 2 [Bos taurus] 1.00 
 616069 N4BP2L1 NEDD4 binding protein 2-like 1 [Bos taurus] 1.96 
 534400 CCDC100 coiled-coil domain containing 100 [Bos taurus] 1.62 
 525698 C8H4orf27 chromosome 4 open reading frame 27 ortholog [Bos taurus] 1.17 
 10007274 ARID5B AT rich interactive domain 5B (MRF1-like) [Equus caballus] 1.46 
 451412 LOC451412 similar to KIAA0280 [Pan troglodytes] 1.13 
 506521 MRPL41 mitochondrial ribosomal protein L41 [Bos taurus] -1.11 
 522515 SGPL1 sphingosine-1-phosphate lyase 1 [Bos taurus] 0.91 
 541187 ATP8B1 ATPase, class I, type 8B, member 1 [Bos taurus] 1.12 
 507010 COL16A1 collagen, type XVI, alpha 1 [Bos taurus] 1.01 
dB EST ID Clone Name M value 
 21994317 4110245 BARC 9BOV Bos taurus cDNA clone 9BOV38_017 5’, mRNA sequence 1.14 
 21609756 UMC-bov-0A01-008-d07 Day 3 Oviduct bov Box taurus cDNA 3’, mRNA sequence 1.07 
 28364486 1367783 MARC 7BOV Bos taurus cDNA 5’, mRNA sequence 1.85 




 21758041 UMC-bov_0A02-009-e07 Day 3 Oviduct bov Bos taurus cDNA 3', mRNA sequence 2.14 
 33993319 Hw_Fat_9_B09 Bos taurus CF-24-HW fat cDNA library Bos taurus cDNA, mRNA sequence 0.94 
 48013890 LB02354.CR_H03 GC_BGC-23 Bos taurus cDNA clone IMAGE:8610293 5', mRNA sequence 1.00 
 41881472 B28691A FFB Bos taurus cDNA clone B2869 3', mRNA sequence 1.52 
 53805706 C0009290H03.Q1KM13R KN510 Bos taurus cDNA clone C0009290H03 3', mRNA sequence 1.85 
 48119692 LB0343.C21_L04 GC_BGC-34 Bos taurus cDNA clone IMAGE:9109590 3', mRNA sequence 0.90 
 48064420 LB03545.CR_F24 GC_BGC-35 Bos taurus cDNA clone IMAGE:8670554 5', mRNA sequence 1.73 
 22983063 UMC-bend_0B02-012-b06 Uterus (endometrium) bend Bos taurus cDNA 3', mRNA sequence -1.46 
 43741903 LB004118.CR_P03 GC_BGC-04 Bos taurus cDNA clone IMAGE:8975669 5', mRNA sequence 1.77 
 53804499 C0009288L06.Q1KM13R KN510 M. bovis infected Bos taurus DC/Mphage/Mo Bos taurus  
  cDNA clone C0009288L06 3', mRNA sequence -1.25 
 40867216 LB02329.CR.1_D21 GC_BGC-23 Bos taurus cDNA clone IMAGE:8270567, mRNA sequence 2.58 
 48010098 LB02340.CR_M09 GC_BGC-23 Bos taurus cDNA clone IMAGE:8605043 5', mRNA sequence 1.02 
 41965501 P98231A FNM Bos taurus cDNA clone P9823 3', mRNA sequence 0.92 
 48152781 LB02353.C21_M01 GC_BGC-23 Bos taurus cDNA clone IMAGE:8610027 3', mRNA sequence 1.32 
 43539218 LB01637.CR.1_H13 GC_BGC-16 Bos taurus cDNA clone IMAGE:8325279 5', mRNA sequence 1.61 
 24792838 UMC-bend_0B02-027-d05 Day 16 Uterus from a pregnant animal bend Bos taurus cDNA 3',  
  mRNA sequence -1.39 
 43569254 LB01840.CR_P11 GC_BGC-18 Bos taurus cDNA clone IMAGE:8830909 5', mRNA sequence 1.25 
 48116062 LB03449.C21_C09 GC_BGC-34 Bos taurus cDNA clone IMAGE:8652035 3', mRNA sequence 1.13 
 36367604 1598932 MARC 11BOV Bos taurus cDNA 3', mRNA sequence 1.75 
 43544222 LB01652.CR_I18 GC_BGC-16 Bos taurus cDNA clone IMAGE:8385308 5', mRNA sequence 1.17 
 48108485 LB03411.C21_D17 GC_BGC-34 Bos taurus cDNA clone IMAGE:8657443 3', mRNA sequence 1.12 
 41890507 A37381A FFB Bos taurus cDNA clone A3738 3', mRNA sequence 0.96 
 53799211 C0009281B14.Q1KM13R KN510 Bos taurus uninfected DC/Mphage/Mo Bos taurus cDNA  
  clone C0009281B14 3', mRNA sequence 1.00 
 53811547 C0009508L13.Q1KM13R KN510 Bos taurus rectum from E. coli challenged/treated animals  
  Bos taurus cDNA clone C0009508L13 3', mRNA sequence -0.96 
 53811547 C0009508L13.Q1KM13R KN510 Bos taurus rectum from E. coli challenged/treated animals  
  Bos taurus cDNA clone C0009508L13 3', mRNA sequence 2.02 
 28667858 UMC-bof_0B02-018-h08 Ovarian follicle early selected bof Bos taurus cDNA 3',mRNA sequence 0.91 
 53809512 C0009505N10.P1KM13F KN510 Bos taurus rectum from E. coli unchallenged animals Bos  
  taurus cDNA clone C0009505N10 5', mRNA sequence 1.06 
 41885977 B54791A FFB Bos taurus cDNA clone B5479 3', mRNA sequence 2.54 




Figure 1: Comparison of directional changes of genes within the microarray used for 
validation.  Microarray fold change (dark bar) and the fold change from the RT-PCR 
(light bar).  Genes that end with a –M are from LM tissue and genes that end with a –F 





















































































Figure 2: 26S proteasome gene expression in longissimus muscle of healthy (HLTH) and 




Figure 3: Haptoglobin gene expression in subcutaneous fat of healthy (HLTH) and 








































P = 0.10 




Figure 4: Ingenuity® Pathway Analysis of both tissues showing genes in the protein 
ubiquitin pathway, glucocorticoid receptor signaling, hepatic fibrosis/hepatic stellate cell 
activation, and PPARα activation.  CP = Pathway identification connecting genes 
involved in specified pathway. Green colored shapes are down-regulated and red are up-
regulated in the microarray.  Solid lines show direct interactions.  Dotted lines are 






Figure 5: Ingenuity® Pathway Analysis from LM and SCF showing the central hub for 
hepatocyte nuclear factor 4, alpha (HNF4A).  Solid lines show direct interactions.  Dotted 
lines show indirect interactions.  Green shapes are down-regulated genes from the 





Figure 6: Ingenuity® Pathway Analysis of SCF showing a central hub for β-estradiol 
and hepatocyte nuclear factor 4, alpha (HNF4A) activation within the SCF tissue.  Red 
colored shapes are up-regulated and green are down-regulated genes from this 
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ABSTRACT: Bovine respiratory disease (BRD) is the most costly disease to the cattle 
industry.  The objective of this experiment was to determine the effects of number of 
antimicrobial treatments for BRD on gene expression in economically important tissues.  
Tissue biopsy samples from the longissimus dorsi muscle (LM) and subcutaneous fat 
(SCF) between the 12th and 13th rib from heifers never treated against BRD (HLTH; n = 
5), treated once (T1; n = 5), treated twice (T2; n = 5), treated three times (T3; n = 5), and 
heifers classified as chronically morbid (CHR; n = 5) were collected after a 63-d 




antimicrobial treatments and had lost BW during the previous 21 d on feed.  Genes (n = 
14) were evaluated using quantitative RT-PCR.  Proc Mixed procedures of SAS were 
used to evaluate significance of number of treatments.  In SCF, components of the 
ubiquitin pathway, F-box and WD repeating domain containing 12 (FBXW12), tended (P 
≤ 0.10) to increase as the number of antimicrobial treatments increased.  In addition, 
expression of FBXW12 tended (P = 0.10) to be greater and expression of 26S 
proteasome subunit ATPase 1 (26S) tended (P = 0.09) to be greater in LM of CHR 
heifers than HTLH heifers.  In LM, fold change expression of tumor necrosis factor-α 
was greater (P = 0.01) in CHR heifers than HLTH, T1 and T2; T3 heifers were 
intermediate.  Haptoglobin (HP) expression in SCF was greater (P = 0.05) in T1 than 
CHR heifers; HLTH, T2, and T3 heifers were intermediate.  Results suggest that genes 
involved in muscle wasting via the ubiquitin pathways and expression of TNF-α may be 
activated in morbid heifers.  These results could partially explain the decreased growth 
rates and carcass quality in cattle infected with BRD. 
 




Bovine respiratory disease (BRD) is the most costly disease in feedlot cattle in the 
United States because it decreases performance and increases medical costs and potential 
carcass discounts.  Clinical signs observed when an animal is experiencing BRD include, 




anorexia the nutritionally deprived animals lose BW resulting in decreased performance.  
Lehnert et al. (2006) used cattle nutritionally deprived for 114 days and observed BW 
loss-mediated muscle atrophy and manipulation of fatty acid profiles.  Therefore, Lehnert 
et al. (2006) proposed that low feed intake, such as in calves experiencing BRD, could 
partially explain long-term decreases in performance and carcass merit. 
Muscle cells have been shown to express receptors for both cytokines and growth 
factors (Broussard et al., 2003).  The magnitude of increases in inflammatory cytokines 
during acute respiratory infection may lead to decreases in protein accretion and growth 
(Escobar et al., 2004).  Cytokines have also been shown to act on skeletal muscle to 
decrease the efficacy of anabolic hormones such as insulin-like growth factor I (IGF-I), 
while also directly influencing the synthesis and degradation of skeletal muscle protein 
(Broussard et al., 2001; Alvarez et al., 2002; Escobar et al., 2004).  Skeletal muscle may 
be an important source of both catabolic and anti-inflammatory cytokines and the balance 
between these two could possibly be involved in the modulation of protein turnover and 
muscle wasting (Alvarez et al., 2002).  Muscle tissue is not only used in contractile 
functions, but also as a protein reservoir that can be mobilized in a stressed state (Cao et 
al., 2005). 
Recent evidence indicates that adipocytes and myofibers are equipped with 
functional pattern recognition receptors, and are capable of responding directly to 
pathogens and other receptor ligands.  Adipocytes and myofibers, acting as functional 
pattern recognition receptors, are active participants in the innate immune response 
producing a number of immune and metabolic regulators, including pro-inflammatory 




1998; Havel et al., 2002; Ding et al., 2004; Gabler and Spurlock, 2007).  For example, in 
adipocytes and muscle cells nuclear factor-kappa B (NF-κB) is activated by bacterial 
lipopolysaccharide and saturated fatty acids that are recognized by toll-like receptor-4 
(TLR-4) pattern recognition which results in local production of tumor necrosis factor-α 
(TNF-α) and interleukin 6 (IL-6).  Adipocytes also work in regulation by being the 
source of adiponectin, an anti-inflammatory hormone, which suppresses the activation of 
NF-κB (Gabler and Spurlock, 2007).  Toll-like receptor-4 is part of a large family of 
receptors that recognize pathogen-associated molecular patterns (Frost et al., 2002).  Toll-
like receptors are sensors of microbial infection and are responsible for the induction of 
both innate and adaptive immune responses.  The mammalian TLR family presently 
consists of ten members, and because of all the many receptors, it provides the immune 
system with the ability to respond to a wide variety of pathogens.  Toll-like receptor-4 
signaling can stimulate IL-6 mRNA expression in mouse skeletal muscle.  Frost et al. 
(2003) observed that mice that have a mutation in the TLR-4 receptor have a greatly 
decreased expression of IL-6. 
Nuclear factor-kappa B is the best defined transcription factor that is activated by 
TLR (Toubi and Shoenfeld, 2004).  Nuclear factor-kappa B is most commonly known to 
be involved in innate and adaptive immunity (Langland et al., 2006; de los Santos et al., 
2007; Takeuchi and Akira, 2007). Nuclear factor-kappa B has been shown to induce the 
expression of IL-1β, TNF-α, and IL-8 in bovine alveolar macrophages exposed to M. 
haemolytica leukotoxin and endotoxin (Hsuan et al., 1999; Caverly et al., 2003).  
Therefore, NF-κB is a central integration site for pro-inflammatory signals and a 




presenting receptors, antigen-presenting receptors, stress response and acute phase 
proteins, and other regulators of apoptosis, growth, and host defense (Cai et al., 2004).   
Tumor necrosis factor-α is known to be important in mediating inflammation and 
cytotoxic reactions and currently it has been thought to have an active role in metabolism.  
Broussard et al. (2003) observed that when IGF-I receptors were stimulated by 
concentrations of lower than 0.1 ng/mL of TNF-α, it inhibited de novo protein synthesis 
by 50% in myoblasts.  Tumor necrosis factor-α has been shown, in chronically high 
concentrations, to result in muscle wasting in skeletal muscle due to increased protein 
turnover (Llovera et al., 1993). 
 Cystic fibrosis (CF) is a disease in humans that is caused by a genetic defect that 
impairs the mucous lining of the lungs.  This predisposes patients to chronic bacterial 
infection in the respiratory tract that causes lung destruction and loss of pulmonary 
function.  Studies suggest that the host inflammatory and metabolic responses to chronic 
pulmonary infection have an impact on maintenance of body composition (Pencharz et 
al., 1984; Stutts et al., 1986; Elborn et al., 1993; Bell et al., 1996; Bell et al., 2000; 
Ionescu et al., 2000; Ionescu et al., 2002).  Changes in body composition are noted to 
possibly come from a negative energy balance resulting from an inadequate energy intake 
to meet energy demands.  Ionescu et al. (2002) summarized that excessive energy 
expenditure in CF may result from the increased energy cost of breathing due to altered 
pulmonary mechanics, catabolic intermediary metabolism due to chronic pulmonary 
infection, or an acute phase inflammatory response with increased circulating 
immunoreactive TNF-α, IL-1, IL-6, and other counter-regulatory hormones.  Several 




and skeletal muscle used as alternative energy sources (Van der Poll and Sauerwein, 
1993; Ionescu et al., 2002). 
 An experiment conducted by Montgomery et al. (2009) showed that during a 36-d 
receiving period ADG decreased linearly with increases in the number of times an animal 
was treated for clinical signs of BRD.  This resulted in heifers with lighter BW going into 
the grazing period, the subsequent finishing phase, and at slaughter.  Carcasses were 
lighter, while fat thickness and marbling scores were lower with increases in the number 
of times treated.  There was also a tendency for decreased LM area (Montgomery et al., 
2009). 
 Because BRD infections lead to decreased performance and carcass merit of 
cattle, our objective was to determine if the number of antimicrobial treatments for 
clinical signs of BRD affects gene expression in muscle and fat tissues.  
 
METHODS AND MATERIALS 
 The experimental protocol was approved by the Oklahoma State University 
Institutional Animal Care and Use Committee.   
Animals 
 Three hundred sixty high-risk heifers (initial BW = 248 ± 14 kg) were purchased 
from multiple auction barns in Kentucky and delivered to the Willard Sparks Beef 
Research Feedlot (WSBRF), Stillwater, OK.  The heifers were individually identified 
and ear-notched to test for persistent infection with bovine viral diarrhea virus as 
described by Fulton et al. (2006).  A heifer identified as PI was removed from the group 




access to prairie hay.  Within 24 hours of arrival heifers were processed.  Initial 
processing consisted of administration of a modified live viral respiratory vaccine 
(IBRV-BVDV Type 1 and 2-PI3V-BRSV, Pyramid 5, Fort Dodge Animal Health, 
Overland Park, KS), a 7-way Clostridial bacterin/toxoid (Vision 7, Intervet/Schering-
Plough Animal Health, DeSoto, KS), and dewormed with a moxidectin (Cydectin, Fort 
Dodge Animal Health, Overland Park, KS).  All heifers were implanted with estradiol 
and trenbalone acetate (Component TE-G, Elanco Animl Health, Indianapolis, IN).  
Seven days after initial processing heifers were re-vaccinated with Pyramid 5 (Fort 
Dodge Animal Health). 
Once moved to assigned pens heifers were offered prairie hay and 1% of BW of a 
diet consisting of (DM basis) 45% dry rolled corn, 15% corn WDGS, 17.5% ground 
alfalfa hay, 17.5% ground grass hay, and 5% pelleted supplement [69.6% wheat 
middlings, 2% limestone, 7.5% salt, 2% magnesium oxide, 0.3% zinc sulfate, 0.14% 
copper sulfate, 0.1% manganous oxide, 0.06% vitamin A (30,000 IU/g), 0.04% vitamin E 
(50%) and 0.25% Rumensin 80 (Elanco Animal Health, Indianapolis, IN)].   
 Heifers were observed daily for signs of BRD by trained professionals as 
described by Step et al. (2008).  Briefly, evaluators used criteria based on the DART 
system (Pharmacia Upjohn Animal Health, Kalamazoo, MI) with modifications.  The 
major observable signs were depression, appetite, respiratory signs, and rectal 
temperature.  The heifers were assigned severity scores ranging from 1 to 4 where a 1 
was assigned for mild symptoms, 2 for moderate, 3 for severe and 4 for moribund.  The 
criterion for antimicrobial treatment was determined by using a combination of the visual 




had to have a rectal temperature of 40˚C or greater before an antimicrobial treatment was 
administered.  If a heifer had a severity score of 3 or 4 she was automatically treated with 
an antimicrobial.  The first antimicrobial treatment was tilmicosin (Micotil 300, Elanco 
Animal Health, Greenfield, IN) at a dosage rate of 10 mg/kg BW.  If a second treatment 
was required (a minimum of 120 hours after first injection for severity scores of 1 or 2; 
72 hours for 3 or 4), the antimicrobial was enrofloxacin (Baytril 100, Bayer Corp, 
Shawnee Mission, KS) at a dosage rate of 10 mg/kg BW.  If a third treatment was needed 
(at least 48 hours after second treatment) ceftiofur hydrochloride (Excenel RTU, Elanco 
Animal Health) was used at a dosage rate of 2.2 mg/kg BW.  Forty-eight hours after the 
third treatment heifers were given another treatment with ceftiofur HCl.  When visual and 
temperature criteria were not met, no antimicrobial was given, and both treated and non-
treated heifers were returned to home pens following evaluation.  Body weight was 
recorded at the time of treatment and on d 63 to determine ADG during the 
preconditioning period. 
 After 63 days on feed, five heifers from the “healthy” (HLTH) group and five 
heifers from the “chronic” (CHR) group were chosen at random to be biopsied from the 
LM and SCF.  Healthy was defined as an animal that had never been pulled for signs of 
BRD or any other disease and were never treated with an antimicrobial for clinical signs 
of BRD.  Chronic was defined as heifers that had been identified as morbid and received 
antimicrobial treatment three times, were identified as being sick a fourth time, and lost 
BW during the previous 21 days.  After the heifers were identified as CHR they were 




described above and given free-choice prairie hay for the duration of the receiving period 
(total 63 days).   
On d 63, biopsies were taken from the SCF and LM.  After using a local 
anesthetic and cutting through the skin, thumb forceps were used to raise the SCF and a 
sample (approximately 100 mg) was removed with scissors.  Biopsies for LM tissue 
followed the procedure described by Winterholler et al. (2008).  Biopsy samples were 
immediately snap frozen in liquid nitrogen, and stored frozen (-80˚C) until further 
processing. 
RNA extraction 
 RNA was extracted from both tissues using TRIzol following the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA).  Briefly, ~0.2 g of tissue was homogenized in 1 mL 
of TRIzol.  The homogenate was clarified by centrifuging at 12,000 × g for 10 min at 
4˚C.  This removed the excess fat, leaving a purer aqueous phase of RNA, DNA, and 
protein.  Chloroform (0.2 mL) was added to the aqueous phase and incubated at room 
temperature for 10 min.  Separation was done by centrifugation at 12,000 × g for 15 min 
at 4˚C.  The aqueous phase (RNA) was removed and precipitated out with isopropanol.  
Ethanol (75%) was included to wash the pellet and then the pellets were dissolved in 
DEPC water.   
 A 1.5% agarose gel with ethidium bromide was used to determine quality of the 
RNA.  The quantity was determined using a Nanodrop™ ND-100 spectrophotometer 
(NanoDrop Technologies, Willington, DE). 




 Initially, a long oligo, whole bovine array from the Bovine Microarray 
Consortium (Elsik, 2006; http://animalsciences.missouri.edu/animalgenomics/bomc.php) 
was used to compare HLTH vs. CHR heifers (Johnson et al., 2009).  Primers for genes of 
interest were designed using a sequence designed from Primer 3 (http://frodo.wi.mit.edu/) 
and Integrated DNA Technologies (IDT, 
http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/) software.  The primer 
sequences, temperatures, and product size are shown in Table 1.  Genes selected for real-
time PCR were chosen based on their function.  The broad categories were the ubiquitin-
proteasome pathway [F-box and WD repeat containing 12 (FBXW12) and 26S 
proteasome (26S)], immunological functions [haptoglobin (HP), chemokine ligand 3 
(CXCL3), and ribosomal protein S19 binding protein 1 (RPS19BP1)], acute phase 
factors (TLR-4, NF-κB, TNF-α, IL-6), and growth and metabolism [homeobox A5 
(HOXA5), cadherin 1 (CADH1), and fatty acid binding protein 5 (FABP5)].  Total RNA 
(1 µg) was used to make cDNA with the QuantiTect® Reverse Transcription kit 
following the manufacturer’s protocol (QIAGEN Inc., Valencia, CA).  The cDNA was 
then used as the template for qRT-PCR.   
 An iCycler real-time detection system (Bio-Rad Laboratories, Inc., Herules, CA) 
was used along with PerfeCTa™ SYBR Green SuperMix for iQ™ (Quanta BioSciences, 
Inc. Gaithersburg, MD) to determine gene expression.  18S was used as the housekeeping 
gene.  An efficiency curve for the reaction was done using five serial dilutions.  
Efficiencies ranged a total of six percentage points.  Thermal cycling conditions were 
95˚C for 30 s, followed by 40 cycles of 95˚C for 15 s, variable annealing temperatures for 




reaction to 95˚C for 1 min, 55˚C for 1 min, and then increasing the temperature by 0.5˚C 
from 55˚C to 94.5˚C.  The samples were analyzed in triplicate. 
 Gene expression changes were calculated as described by Livak and Schmittgen 
(2001).  A cycle threshold (CT) was assigned to each of the samples.  A ∆CT value was 
calculated for each replicate by subtracting 18S rRNA CT from the corresponding gene 
samples CT.  An average of the replicates was utilized to compare the gene expression 
levels.  Fold change was calculated by determining the ∆∆CT.  This was accomplished by 
subtracting expression levels for each treatment from the highest expression and plugged 
into the formula: fold change = 2-∆∆CT. 
Statistics 
 The experiment was a completely randomized design.  Data were analyzed using 
the PROC MIXED procedure of SAS, and means were separated using the pdiff 
statement (SAS Inst., Inc., Cary, NC).  Results are discussed as significant if P < 0.05 and 




 Biological data are shown in Table 2.  From d 0 to 63, ADG (kg/d) generally 
decreased (P < 0.001) as the number of treatments for BRD increased.   
Real time RT-PCR 
 In SCF, expression of FBXW12 tended (P = 0.09) to increase as the number of 
antimicrobial treatments increased (Figure 1).  Fold change expression of FBXW12 was 




intermediate.  In addition, CHR heifers tended (P = 0.06) to have greater expression of 
FBXW12 in SCF than HLTH heifers (Figure 2).  In LM, FBXW12 did not differ (P = 
0.39) among treatments (Figure 3).  However, when HLTH vs. CHR were compared, 
expression of FBXW12 tended (P = 0.10) to be greater in CHR than HLTH heifers 
(Figure 4).  Similar to FBXW12, there was no difference (P = 0.13) in expression of 26S 
among treatments in LM (Figure 5).  However, when HLTH vs. CHR were compared, 
expression of 26S tended to be greater (P = 0.09) in CHR compared with HLTH heifers 
(Figure 6). 
Expression of NF-κB (P = 0.49) and TNF-α (P = 0.92) in SCF were not different 
among treatments (Figures 7 and 9).  When comparing CHR vs. HLTH, NF-κB was not 
different (P = 0.12) in SCF (Figure 8).  However, in LM fold change expression of TNF-
α was greater (P = 0.01) in CHR heifers than HLTH, T1 and T2; T3 heifers were 
intermediate (Figure 10).  TNF-α was also greater (P < 0.01) in CHR heifers vs. HLTH 
heifers (Figure 11).  Toll-like receptor-4 and IL-6 were not different (P > 0.10) among 
treatments in either tissue (data not shown). 
Haptoglobin expression in SCF was greater (P = 0.05) in T1 than CHR heifers; 
HLTH, T2, and T3 heifers were intermediate (Figure 12).  In the HTLH vs. CHR 
comparision HLTH heifers had greater (P = 0.03) expression of this gene than CHR 
heifers (Figure 13).  Expression of other genes related to immune response (ITGB8, 








Several factors play a role in the decreased performance observed in cattle treated 
for BRD.  In the present experiment, we observed that with the increase in number of 
times an animal was treated for clinical signs of BRD there were increases in expression 
of components of the ubiquitin pathway in fat and muscle.  Several experiments have 
suggested that the ubiquitin pathway, if over stimulated, can lead to chronic muscle 
wasting (reviewed by Cao et al., 2005).  Specifically, atrophy of muscle occurs through 
activation of the ubiquitin-proteasome pathway.  Proteins tagged with a combination of 
three different ubiquitins (E1, E2, and E3) are recognized and then degraded by the 26S 
proteasome.  Expression of the E3 atrogin-1 has been shown to be eightfold greater in 
atrophied muscle from mice due to fasting (Gomes et al., 2001).  The bovine equivalent 
of atrogin-1 is FBXW12.  In the present experiment, the combination of this pathway 
along with the increase in TNF-α could explain the decreased ADG in CHR heifers.  
Tumor necrosis factor-α has been shown to activate muscle protein degradation via the 
ubiquitin and ATP-dependent proteolytic pathways (Garcia-Martinez et al., 1993).  
Tumor necrosis factor α in skeletal muscle of humans and animals with muscle wasting 
disease has been related to cachexia (Argilés et al., 2000). 
Interestingly, in the present experiment FBXW12 was expressed in SCF with 
increases in the number of times a heifer was treated for clinical signs of BRD.  The 
ubiquitin pathway is well documented to cause muscle wasting but the potential function 
of this pathway in SCF is not understood.  A study by Cooke et al. (2007) used mice to 
look at F-box protein S kinase-associated protein 2 (Skp2), which is in the same family 




Degradation of two cyclin-dependent kinase inhibitors involved in adipogenesis was 
activated by Skp2.  Degradation of the inhibitors resulted in a decrease in subcutaneous 
fat due to both size and number of adipocytes (Cooke et al., 2007).  Similar results in the 
bovine might explain the decrease in fat depots observed in cattle treated for BRD.  
Chibisa et al. (2008) showed that BW and fat loss in dairy cows were related to the up-
regulation of the ubiquitin-proteasome pathway.  Chibisa et al. (2008) fed propylene 
glycol to early lactation dairy cows and observed a tendency for decreased mRNA 
expression of several ubiquitin family genes in muscle. 
In the present experiment, Hp gene expression was greater in SCF of HLTH and 
T1 heifers compared with CHR heifers.  White adipose tissue is a primary source of HP 
mRNA, but brown adipose tissue can also express this gene (do Nascimento et al., 2004).  
An experiment conducted by do Nascimento et al. (2004) used 3T3-L1 adipocytes to 
determine changes in HP mRNA due to cytokines, catecholamines, and PPARγ.  They 
observed that LPS, TNF-α, and IL-6 substantially increased HP mRNA.  Dexamethasone, 
noradrenaline, isoprenaline, and β3-adrenoceptor agonist also increased expression of 
HP, while nicotinic acid and PPARγ agonist decreased mRNA expression of HP (do 
Nascimento et al., 2004).  Haptoglobin is an acute phase protein and has been evaluated 
in several experiments as an indicator of inflammation and disease.  In the present 
experiment, Hp was more highly expressed in HLTH heifers than in CHR heifers.  Our 
results suggest that Hp may become less responsive with increased incidences of BRD. 
In general, genes related with growth/metabolism (e.g., CADH1, FABP5) were 
not affected by treatment in the present experiment.  Due to the established link between 




differences were negligible or missed due to the timing of tissue sampling in relation to 
the BRD events, or changes in genes related to the ubiquitin-proteasome pathway and 
immune function are mostly involved.   
 
CONCLUSIONS 
Genes involved in the ubiquitin-proteasome pathway, immunological function 
and the acute phase response were differentially expressed in the present experiment, 
especially for chronic heifers.  These results may help explain observed differences in 
growth and carcass merit in cattle treated multiple times for BRD.  Because our sampling 
protocol was at a single time point, a follow-up experiment may involve sampling at the 
time a heifer/steer is treated for clinical signs of BRD.  Understanding gene expression 
changes at the time of treatment could potentially help in decreasing the detrimental 
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Table 1: RT-PCR primers         
   





26S LM Forward 5’-CAGTGATGAAGGTGGAAAAGG-3’ 184 59 506238 
  Reverse 5’-GCGGACCATAGAGAATGACC-3’    
CADH1 SCF Forward 5’-CGTTTCCTAAGTCGCTGGTC-3’ 272 55.5 282637 
  Reverse 5’-GGGCTTGTTGTCATTCTGGT-3’    
CATHL5 SCF Forward 5’-AGGACGATGAGAACCCAAAC-3’ 112 58 282167 
  Reverse 5’-CCACACACTCTTTCAGCAGC-3’    
CXCL3 LM Forward 5’-GCCAAACCGAAGTCATAGCC-3’ 249 58 613667 
  Reverse 5’-AAATAGTCCAGCACATCAAGTCC-3’    
FABP5 LM Forward 5’-ATGGCTCTGCGAAAAGTGG-3’ 145 59 281760 
  Reverse 5’-GCTGTGGTCTCTTCAAACTTCTC-3’    
HOXA5 LM & SCF Forward 5’-GACCTCGTTTAGTGCCAATG-3’ 224 62-LM 768039 
  Reverse 5’-CAGAGTCACAGTTTTCGTCACAG-3’  61-SCF  
HP SCF Forward 5’-CGTGTGGGTTATGTGTCTGG-3’ 275 62 280692 
  Reverse 5’-GTGTCGTCTTCCTTGTCGTG-3’    
ITGB8 SCF Forward 5’-CAGTTTCACCATACATTAGCATCC-3’ 244 58 3696 
  Reverse 5’-AGCCTCTTTTCGCCATCC-3’    
RPS19BP1 LM & SCF Forward 5’-CAGGAGAACCAGGAAGAAACC-3’ 152 62-LM 509108 
  Reverse 5’-TAGAACCCGAAGCCTACCC-3’  61-SCF  
TRA1 LM Forward 5’-TCTTGCTGTGGTTTTGTTTG-3’ 238 58 282646 
  Reverse 5’-TTGTTCTTCCTCGTCTGTTCC-3’    
TLR-4 LM&SCF Forward 5’-ACGAAAGCAGAAAGCCACAG-3’ 265 59 281536 
  Reverse -GGTTACGGGAGGAGAGGAAG-3’    
NF-κB LM&SCF Forward 5’-GAGAGTGCTGGTGAAATGAGG-3’ 287 58 540361 
  Reverse 5’-TTTGCTGTTTGGTCTGTTGG-3’    
TNF-α LM&SCF Forward 5’-CCTCAGCCTCTTCTCCTTCC-3’ 195 58 280943 
  Reverse 5’-TCTTTCCCCATCAACACACC-3’    
IL-6 LM&SCF Forward 5’-ACTTCTGCTTTCCCTACCCC-3’ 233 57.5 280826 






Table 2: Biological data of heifers treated for BRD. 
 Treatments1 
Item HLTH T1 T2 T3 CHR 
ADG, kg/d2 1.52 ± 0.07 1.33 ± 0.08 0.87 ± 0.07 0.53 ± 0.06 0.61 ± 0.10  
Days on feed      
1st treatment  16 ± 14 5 ± 2.1 3 ± 2.4 2 ± 1.5 
2nd treatment   16 ± 4.7 12 ± 2.6 8 ± 2.2 
3rd treatment    20 ± 3.9  13 ± 5.3 
Days to 
removal3 
    32 ± 12.7 
1Treatments were healthy (HLTH), treated once (T1), treated twice (T2), treated 
three times (T3), and chronic (CHR). 
2ADG differed (P < 0.001) among treatments. 







Figure 1: Fold change expression of FBXWD12 in SCF.  There was a tendency for an 
increase in expression of FBXW12 with increases in the number of times and animal was 
treated for clinical signs of BRD (P = 0.09).   
a,bFold changes with different superscript letters differ (P < 0.01).   
 
 
Figure 2: Fold change expression of FBXWD12 in SCF.  Chronic heifers had a greater 





























F-box and WD containing repeat domain 





















Figure 3: Fold change expression of FBXW12 in LM tissue.  There was no difference 
among treatments (P = 0.39).  Means separation indicated that CHR heifers tended (P = 
0.07) to have greater expression than HTLH heifers. 
 
 
Figure 4: Fold change expression of FBXW12 in LM tissue.  Gene expression tended (P 
















































Figure 5: Fold change expression of 26S in LM tissue.  There was no difference (P = 
0.13) among treatments. Means separation showed that HLTH and T3 heifers had lower 
(P ≤ 0.05) expression of 26S than T1, T2, and CHR heifers. 
 
 
Figure 6: Healthy versus chronic fold change expression of 26S in LM tissue.  26S 














































Figure 7: Fold change expression of NF-κB in SCF tissue.  NF-κB was not different 
among treatments (P = 0.49). 
 
 
Figure 8: Healthy versus chronic fold change expression of NF-κB in SCF tissue.  NF-













































Figure 9: Fold change expression of tumor necrosis factor-α (TNF-α) within SCF tissue.  




Figure 10: Fold change expression of tumor necrosis factor-α (TNF-α) in LM tissue. 
TNF-α was different among treatments (P = 0.01). 




Figure 11: Healthy versus chronic fold change expression of tumor necrosis factor-α 










































































Figure 12: Fold change expression of haptoglobin (HP) in SCF.  Haptoglobin was 
different among treatments (P = 0.05).   




Figure 13: Healthy versus chronic fold change expression of haptoglobin (HP) in SCF 
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